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ABSTRACT 
One of the hallmarks associated with cancer is an aberrant expression of glycans decorating the 
plasma membrane due to altered expression of glycosyltransferases. The elevation of 
sialyltransferase ST6Gal-I and of its cognate glycan structure Sia6LacNAc has been described 
in colon and other cancers and controversially associated with malignancy. In this study, we 
investigated the relationship between ST6Gal-I mRNA expression and clinical features in a 
cohort of over 600 colorectal cancer (CRC) cases on The Cancer Genome Atlas, finding that 
low ST6Gal-I expression was associated with a microsatellite unstable and mucinous 
phenotype, and with BRAF mutation, but not with clinical stage or survival.  
To investigate the effect of ST6Gal-I overexpression on CRC, we retrovirally transduced with 
the human ST6Gal-I cDNA or with an empty vector the cell lines SW48 (microsatellite 
unstable) and SW948 (chromosomal unstable), generating their ST and NC variants 
respectively. Transcriptomic analysis of the two cell lines revealed a higher number of 
modulated genes in SW948 ST compared with SW48 ST. SW948 ST (but not SW48 ST) 
displayed an accelerated apoptotic response compared to NC, while SW948 ST (but not SW48 
ST) displayed increased ability to heal the wound than SW948 NC. In soft agar assay, SW948 
ST (but not SW48 ST) cells generated fewer clones, although bigger, than SW948 NC. SW48 
ST (but not SW948 ST) displayed a reduced capacity to invade Matrigel compared to NC. 
Treatment with HGF caused an increase of FAK phosphorylation in SW948 NC cells and a 
decrease in ST cells. Similar results were observed in SW48 NC and ST cells. With ALDH 
staining we observed a population of cancer stem cells in the two cell lines with no differences 
derived from ST6Gal-I overexpression. These results indicate a very cell type specific effect of 
ST6GAL1 and Sia6LacNAc on the phenotype of CRC cells.  
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1. INTRODUCTION 
 
1.1. GLYCOSYLATION 
Glycosylation is one of the most important post-translational modifications occurring inside the 
cell. It consists in the glycosidic linkage of glycans to secretory and membrane-anchored proteins 
or lipids (1). It is known that glycans have important roles in protein folding and stability, cell 
adhesion, signalling, cell-cell recognition in fertilization and immune response (2), apoptosis and 
cell survival (3) as well as in antibody recognition (4). The many glycosylated proteins expressed 
on the plasma membrane contribute to form the glycocalyx. The impairment of the glycosylation 
process causes the genetic diseases called Congenital Disorders of Glycosylation (CDG), which 
appear in infants and cause malfunctions of several organs including central nervous system, 
muscle and intestine (5), often incompatible with life. 
The glycosylation process occurs in the endoplasmic reticulum (ER) or in the Golgi apparatus, 
involving many glycosyltransferases, the enzymes that catalyse the transfer of a sugar from an 
activated nucleotide-sugar donor to another sugar, a protein or a lipid. There are two main types of 
glycan chains that can be added on proteins, they differ in the amino acid used for the glycosidic 
linkage and in the sequence of reactions that lead to the synthesis of the glycan: O-linked and N-
linked. 
O-linked glycosylation is developed in the Golgi apparatus and it is characterized by the addition 
of sugars to the oxygen atom of serine/threonine (Ser/Thr) residues of the polypeptide chain. 
Mucins are the most common O-linked glycoproteins and their biosynthesis starts in  cis Golgi by 
the addition of a N-acetylgalactosamine (GalNAc) residue operated by the peptide:GalNAc-
transferases (6) and can be followed by the transfer of galactose (Gal), N-acetylglucosamine 
(GlcNAc), sialic acid and fucose creating linear or branched chains (7). There are also non-
mucinous types of O-linked glycoproteins where the sugar linked to Ser/Thr is different from 
GalNAc and could be fucose, xylose, mannose, GlcNAc, galactose or glucose (Glc) (8).  
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N-linked glycoprotein biosynthesis is more complex and organized than O-linked glycosylation. 
In fact, it starts in the endoplasmic reticulum where the dolichol phosphate (Dol-P) is used as carrier 
to build an  oligosaccharide comprised of 3 glucose, 9 mannose (Man) and 2 GlcNAc residues (9) 
forming the lipid-linked oligosaccharide (LLO). The first steps occur in the cytoplasmic side of the 
ER membrane and involve glycosyltransferases encoded by the ALG (Asparagine Linked 
Glycosylation) genes that add two GlcNAc and five mannose residues forming the branched 
structure Man5GlcNAc2 (10). At this point, the RFT1 enzyme translocates the LLO on the luminal 
side of the ER where its biosynthesis continues with the progressive addition of four mannose and 
three glucose residues operated by α-mannosyltransferases and α-glucosyltransferases (11). The 
final structure is conventionally formed by three antennae (a, b and c) and it is terminated by the 
addition of the “capping” α-1,2-linked glucose on the a-antenna, which determines the substrate 
recognition by the oligosaccharyltransferase (OST) (12). The biosynthesis of the LLO is 
fundamental for the N-linked glycosylation, in fact, deficiencies in this process result in 
hypoglycosylation of proteins which is the primary cause for the severe clinical signs observed in 
CDG (5). The OST is the central enzyme of the pathway because it catalyses the addition of the 
LLO on the asparagine residue of the consensus sequence N-X-S/T  (where X could be any amino 
acid but proline) of a forming polypeptide chain before the protein folding takes place (Fig. 1.1) 
(12).  
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Fig. 1.1 N-linked glycosylation process starts in the ER with the lipid-linked oligosaccharide biosynthesis catalysed 
by enzymes encoded in the ALG loci. GlcNAc transferases and Man transferases acting in the cytoplasmic side of the 
ER use UDP-GlcNAc (blue box) and GDP-Man (green box), respectively. The LLO composed by Man5GlcNAc2 is 
transferred to the ER lumen and further processed by lumen-oriented glycosyltransferases to obtain Glc3Man9GlcNAc2 
oligosaccharide. This is then transferred on a selected asparagine residue of a growing polypeptide (12). 
 
The N-linked chain undergoes further processing through the action of glycosidases. In fact, the 
three-terminal glucose are trimmed by α-glucosidase I and II, followed by the removal of four 
mannose residues catalysed by α-mannosidase I (13). Then, the enzyme GlcNAc-transferase I 
(GlcNAcT-I) transfers the first GlcNAc residue to the chain while the α-mannosidase II removes 
two additional mannose residues. The successive step is catalysed by the GlcNAc-transferase II 
(GlcNAcT-II) that adds a second GlcNAc residue to the N-glycan (14). This structure can be further 
implemented in the Golgi apparatus by the action of many glycosyltransferases creating a 
heterogeneous collection of mature glycoconjugates (7). In fact, the N-linked chains can be 
completed by the addition of galactose residues performed by members of the β-1,4-
galactosyltransferase (β1,4 GalT) family, or by the addition of a fucose residue linked to the first 
GlcNAc of the chain (core-fucose) operated by Fucosyltransferase VIII (FucT-VIII). In addition, a 
third GlcNAc residue can be linked to the innermost mannose residue by the enzyme GlcNAc-
transferase III (GlcNAcT-III) creating the bisecting GlcNAc structure. This sugar residue is not 
elongated further. Each antenna can be terminated by a α-2,3- or α-2,6-linked sialic acid residue 
(Fig. 1.2). While the addition of α-2,3-linked sialic acid can be operated by Sialyltransferases 
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ST3Gal-III (15), ST3Gal-IV (16) or ST3Gal-VI (17), the addition of α-2,6-linked sialic acid can 
be mediated only by ST6Gal-I (18). In fact, the second ST6Gal (ST6Gal-II) shows negligible 
activity towards glycoprotein substrates (19, 20).   
Fig. 1.2 Biosynthesis of N-linked glycans in the Golgi apparatus. The Glc3Man9GlcNAc2 oligosaccharide transferred 
on an asparagine residue undergoes further processing by the sequential removal of 3 Glc residues, mediated by α-
glucosidases (αGlcase) I and II, and 4 Man residues, mediated by α-mannosidases (αManase). The first GlcNAc residue 
is transferred to the chain by the GlcNAcT-I. Then, other 2 Man residues are trimmed by αManase II and the second 
GlcNAc residue is added by GlcNAcT-II. This structure can be further modified by the addition of galactose residues, 
by members of the β1,4GalT family or by core-linked fucose (mediated by FucT-VIII) or bisecting GlcNAc (by 
GlcNAcT-III). The sugar chains are frequently terminated by the addition of sialic acids linked either via α2,3 or α2,6 
to galactose (14). 
 
Additional branches with similar or different structures can be linked to the two α-linked mannose 
residues, giving rise to tri- and tetra-antennary structures. The terminal portions of these branches 
can be decorated by various sugar epitopes. It is important to notice that glycosylation, unlike 
protein or DNA synthesis, is a stochastic process. In fact, it depends on the abundance of 
glycosyltransferases, glycosidases and nucleotide-activated sugar donors. Therefore, it is common 
to find a certain degree of heterogeneity in the sugar chains linked to a specific glycosylation site 
in a given glycoprotein (14). 
 
 
5 
 
1.1.1. Glycosyltransferases 
Glycosyltransferases are a family of enzymes responsible for transferring a sugar residue from a 
donor (nucleotide sugar) to polypeptide chains, lipids or other sugars through the formation of α- 
or β-glycosidic linkage. They are principally located in ER and Golgi membranes. They are defined 
by the sugar that they transfer, by the type of linkage that they catalyse and by the acceptor of their 
enzymatic activity. Glycosyltransferases are grouped into 105 families considering their catalytic 
activity in the Carbohydrate Active Enzymes database (CAZy) (21). The glycosyltransferases 
found in the Golgi are type II transmembrane proteins composed of a short N-terminal cytoplasmic 
portion, a transmembrane sequence and a globular catalytic domain in the Golgi lumen. 
 
1.1.2. Sialyltransferases 
Sialylation consists in the transfer of a sialic acid to the oligosaccharide chain. Sialic acids are 
constituted of a nine-carbon backbone with a negative charge at physiological pH. Among the 
different types of sialic acids, the most common in human is N-acetylneuraminic acid (Neu5Ac) 
that can be linked via α2,3- and α2,6-linkage to galactose containing glycans or via α2,6 bond to 
GalNAc and GlcNAc residues (22). In addition, sialic acid can be linked through a 2,8 bond to 
another sialic acid, forming polysialic acids. These different linkages are catalysed by a family of 
enzymes called sialyltransferases that share the same sugar donor, CMP-sialic acid (23). It has been 
reported that an increase in sialylation is closely associated with cancer, mainly because of altered 
expression of sialyltransferases (24-26). Basic properties of cancer cells such as reduced 
intercellular adhesion and increased adhesion to endothelial cells which are crucial for 
metastatisation can be regulated by sialic acids. In fact, sialic acids could prevent cell-cell 
interaction because of its negative charge that create a repulsive effect while sialylated glycans can 
be recognized by cell adhesion molecules such as selectins and siglecs. 
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1.1.3. β-galactoside α2,6-sialyltransferase 1 (ST6Gal-I) 
β-galactoside α2,6-sialyltransferase 1 (ST6Gal-I) is a sialyltransferase that catalyses the transfer of 
a sialic acid to a galactose with a α2,6-linkage and is comprised of 406 amino acids (UniProtKB 
P15907) with a predicted molecular weight of 46 kDa. ST6Gal-I belongs to the GT29 family of the 
CAZy database. ST6Gal-I is a type II membrane protein that resides in the trans-Golgi, but a 
truncated form of the enzyme can be secreted and found in body fluids (27). This protein is 
comprised of a short N-terminal cytoplasmic tail followed by the transmembrane domain linked to 
a large luminal catalytic domain (18). ST6Gal-I expression is regulated at transcriptional level from 
tissue-specific promoters resulting in different mRNA species diverging at the 5’end (28). Tree 
major isoforms of ST6Gal-I mRNA have been identified. The first one was isolated from a placenta 
library (29) and is constituted by the exons Y and Z at the 5’-untranslated region (30). This isoform 
is considered the most widely expressed. A second isoform which is mainly expressed by the liver 
(hepatic form), lacks the Y and Z exons but presents a short sequence in front of exon I (31). The 
third isoform is expressed mainly in B-lymphocytes and contains the 5’-untranslated exon X (X 
form) (Fig. 1.3) (32). It has been reported that the hepatic form is expressed in colon cancer (33), 
this suggests that the malignant transformation alters its transcriptional regulation. Xu et al. 
demonstrated that the accumulation of the hepatic form in colon cancer was due to the activity of 
the transcription factor HNF1 (hepatocyte nuclear factor 1) and to its dimerization cofactor 
(DCoH/PCD). While HNF1 was expressed both in normal and cancer tissue, DCoH/PCD was 
abundantly expressed only in colon cancer specimens suggesting the idea that the overexpression 
of this cofactor can be fundamental for ST6Gal-I accumulation in colon cancer (34). After these 
tissue specific exons, the ST6Gal-I gene encodes six exons. Translation starts inside exon two and 
stops inside exon six. Consequently, the three isoforms generate identical peptides.       
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Fig. 1.3 Schematic representation of ST6Gal-I mRNA transcript variants. The three isoforms differ in the 5’UTR 
sequence. The hepatic form presents a small sequence at the beginning of exon I, the form 2 encodes for exon X in the 
5’UTR, while form 3 is characterized by exon Y and Z. These mRNA variants are regulated by three different 
promoters (34). 
 
1.2. COLORECTAL CANCER 
Colorectal cancer (CRC) is the third most common type of cancer among men and the second 
among women worldwide (35). It arises usually through a progressive accumulation of genetic and 
epigenetic alterations. Two main mechanisms are at the basis of the colorectal carcinogenesis. The 
classical adenoma-carcinoma sequence (36) in which both copies of the adenomatous polyposis 
coli (APC) gene must be inactivated by genetic or epigenetic mechanisms, allowing adenoma 
growth. β-catenin, which is no longer inhibited by APC, translocates to the nucleus where it forms 
a transcriptional complex with TCF (transcription Factor), promoting the expression of 
proliferation-promoting genes, such as cyclin D1 and MYC (myelocytomatosis viral oncogene). A 
second mutational event of this pathway consists in the activation of KRAS (Rat sarcoma), while 
the inactivation of SMAD2 and SMAD4, which are effectors of transforming growth factor β 
(TGF-β) signalling, is usually a third event. It should be emphasized that TGF-β normally behaves 
as a cell cycle inhibitor. Loss of TP53 function and other tumour-suppressor genes leads to cancer 
development. This pathway is usually associated with instability of the number and structure of 
chromosomes and is consequently referred to as chromosomal instability (CIN) phenotype (Fig. 
1.4).  
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Fig. 1.4 Molecular and morphological alterations that lead to carcinogenesis in the classical adenoma-carcinoma 
sequence. The first mutation occurs in one allele of the APC gene (first hit), followed by the second allele (second hit). 
Other mutations affecting KRAS, TP53, SMAD2/4 or telomerases, lead to the formation of adenoma and then 
carcinoma (37).  
The second main mechanism is based on the inactivation of genes involved in the DNA repair 
process known as "mismatch repair" (Fig. 1.5) (38). These genes, which include MLH1 (mutL 
homolog 1) and MSH2 (mutS homolog 2), can be inactivated in the germline, leading to Lynch 
syndromes, or sporadically. In both cases, their inactivation leads to the instability of short repeated 
DNA sequences known as microsatellites. Tumours displaying this phenotype are referred to as 
microsatellite instable (MSI). Although the microsatellite regions are often confined in non-coding 
regions of the genome, in a few cases there are short repeated sequences inside the coding regions 
of genes controlling cell growth and apoptosis. Examples are provided by the TGF-β receptor, 
whose mutation leads to loss of TGF-β signalling and by the pro-apoptotic gene BCL2 Associated 
X (BAX). A subgroup of the MSI cancer in which the inactivation of the mismatch repair genes is 
due to their promoter hypermethylation rather than mutation is referred to as CIMP 
(hypermethylation phenotype) (39). Usually, these cases are characterized by mutations of BRAF 
(Rapidly Accelerated Fibrosarcoma B) and wild type RAS and TP53. From a morphological point 
of view, it is possible to describe two different ways: the classical adenoma-carcinoma sequence 
starting with premalignant lesions such as adenomas, and the serrated neoplasia pathway that 
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begins with serrated adenomas or hyperplastic polyps (40). CIN and MSI are usually responsible 
for the classical adenoma-carcinoma pathway and for the serrated neoplasia, respectively. 
 
Fig. 1.5 Molecular and morphological modifications associated with microsatellite unstable pathway which is caused 
by mutation in mismatch repair genes (MLH1, MSH2). This permits the accumulation of mutations in various genes 
leading to carcinogenesis (37). 
Although the mutational events which characterize the two main transformation pathways are 
different, their functional consequences can be partially overlapping.  For example, instead of 
having the loss of function in APC, CRC aroused by MSI have mutations in β-catenin (41).  
Moreover, inactivation of the growth inhibitory pathway based on TGF-β signalling can be 
achieved by SMAD2 and SMAD4 inactivation or by TGF-β receptor inactivation. 
 
1.3. GLYCOSYLATION IN CANCER 
Alterations in glycan display has become a well-known hallmark of cancer cells. In fact, cancer 
cells express a variety of glycan-structures that are different from the ones present in normal tissue 
(42). In their work Hakomori and Kannagi defined two main mechanisms responsible for the 
tumour-associated alteration of  carbohydrate  chains: the incomplete synthesis and the neo-
synthesis process (43). The incomplete synthesis is more frequent in early stage tumours and is 
driven by the impairment of the normal synthesis process of complex glycans (44). This leads to 
the biosynthesis in cancer cells of truncated structures. On the other hand, the neo-synthesis is 
typical of advanced stage tumours and it is due to the cancer-associated expression of specific  
glycosyltransferases (44). Various factors are responsible for the altered glycosylation present in 
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cancer cells: the under- or overexpression of glycosyltransferases, due to dysregulation at the 
transcription level; changes in the tertiary structure of the acceptor protein; availability of the 
acceptor substrate or of the sugar nucleotide donors and the correct expression and localization of 
the glycosyltransferases in the Golgi apparatus (45). The most common cancer-associated 
modifications in glycans structures regard sialylated and fucosylated structures, O-linked glycans 
truncation and N- and O-linked chains branching (45). In the following sections, some of the most 
relevant cancer-associated structures will be briefly reviewed. 
 
1.3.1. Truncated O-linked glycans 
The T or Tn antigens and their sialylated forms are examples of shortened or truncated glycans  
(45). In particular, the expression of peptide:GalNAc transferases is often altered in cancer leading 
to aberrant O-linked glycosylation or synthesis of truncated chains (46). A single GalNAc residue 
linked to serine or threonine is referred to as Tn antigen. Its α2,6-sialylated counterpart, synthesized 
mainly by sialyltransferase ST6GalNAc-I (47), is referred to as sialyl-Tn and is a well-known 
cancer-associated structure, widely expressed in cancer such as pancreas, stomach, colorectal, 
breast, bladder and ovary correlating with poor prognosis (45, 48) and malignancy (49). Therefore, 
it has been proposed as prognostic marker and as a target for the development of anti-cancer 
vaccines (50). Elongation of the Tn antigen by a β1,3-linked galactose (Fig. 1.6) leads to the 
biosynthesis of the Thomsen-Friedenreich (T) antigen, while the further addition of α2,3-linked 
sialic acid, mediated by ST3Gal-I, forms the sialyl-T antigen. Collectively, T, Tn and their 
sialylated variants are often referred to as Thomsen-Friedenreich-related antigens (51) (for the 
structure refer to fig. 1.6). In breast epithelium, the neoplastic transformation increases the presence 
of T and sialyl-T structures, probably due to a down-regulation of the competing enzyme core 2 
β1,6GlcNAcT and up-regulation of ST3Gal-I(52). However, data on mice suggested that the 
responsible for cancer progression could be ST3Gal-I and its tumour-promoter activities, but not 
the expression of the cognate sT antigen. Both, ST3Gal-I (53) and ST6GalNAc-I (54) are involved 
in bladder cancer. In particular, high ST6GalNAc-I and sTn expression correlate with a better 
response to the adjuvant therapy with Bacillus Calmette-Guerin (BCG) (55). Probably this is due 
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to a down-regulation of genes preserving genomic stability in ST6GalNAc-I expressing cells 
resulting in increased sensitivity to the oxidizing agents released by BCG (56). 
 
 
Fig. 1.6 Structure and biosynthesis of Thomsen-Friedenreich-related antigens. The Ser/Thr-linked GalNAc (Tn 
antigen) can be elongated by the addition of either β1,3 linked Gal (T antigen) operated by β1,3GalT or α2,6-linked 
sialic acid (Sialyl-Tn antigen) by ST6GalNAc-I. The elongation of the Tn antigen with a β1,3-linked GlcNAc by 
β1,3GlcNAcT leads to the formation of a core 3 structure. The T antigen can be elongated by the addition of a α2,3-
linked sialic acid forming the Sialyl T antigen or by the addition of a β1,6 GlcNAc leading to the formation of a core 
2 structure. (25) 
 
1.3.2. Core fucosylation 
Core fucosylation is catalysed by FucT-VIII and consists in the addition of a fucose residue to the 
innermost residue of GlcNAc on N-linked chains. It has been reported that FucT-VIII is up-
regulated in lung and breast cancer (57, 58) and that the fucosylated form of α-fetoprotein is a good 
marker for early detection of hepatocellular carcinoma (59). Moreover, in breast cancer the core 
fucosylation of epidermal growth factor receptor (EGFR) triggers dimerization and 
phosphorylation of the receptor, thus increasing EGFR-mediated signalling (57). 
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1.3.3. Branching and bisecting GlcNAc glycans 
Many cancer cells express on their surface complex β1,6-branched N-linked glycans due to an 
increased activity of the enzyme GnT-V encoded by MGAT5 gene (45). Interestingly, MGAT5 
expression is regulated by the Ras signalling pathway, which is commonly activated in cancer (60). 
Its overexpression in lung epithelial cell lines induces increased cell motility and tumour formation 
in athymic mice (61). Moreover, GnT-V seems to be responsible for early events in the formation 
of breast carcinoma in Her2-transgenic mice (62). The data are confirmed by the suppression of 
tumour growth and metastasis in mice deficient for MGAT5 (63). 
On the other hand, bisecting GlcNAc is synthetized by the enzyme GnT-III encoded by the gene 
MGAT3. It has been reported that MGAT3 acts as a tumour-suppressor gene in cancer, reducing 
metastasis (64). In fact, it regulates the glycosylation of EGFR, integrins and cadherins (60). 
 
1.3.4. Sialyl-Lewis antigens 
Sialyl Lewis antigens sialyl Lewisa (sLea) and sialyl Lewisx (sLex) (for the biosynthetic pathway 
refer to fig. 1.7) derive from the α2,3 sialylation followed by the α1,4 (in sLea) or α1,3 (in sLex) 
fucosylation of a type 1 or a type 2 chain, respectively. The enzyme responsible for the α2,3 
sialylation in sLea antigen is ST3Gal-III, while ST3Gal-III, -IV or -VI catalyse the reaction in sLex 
antigen. The final step of sLea and sLex biosynthesis consists in the addition of α1,3- or α1,4-linked 
fucose catalysed by FucT-III (sLea) or FucT-III, -IV, -V, -VI, -VII (sLex). When expressed by 
leukocytes, the original function of these structures is to bind to E- and P-selectins expressed on 
activated endothelial cells. However, they can be ectopically expressed by cancer cells, conferring 
the capacity to spread and metastasise (65). In particular, their expression is reported in lung 
carcinoma, colon, stomach and kidney (66). The sLea tetrasaccharide is a cancer-associated marker 
widely used in clinical practice because it is the epitope of the Ca19-9 antigen (67). The aberrant 
expression of sLea and sLex is probably multifactorial and strongly tissue-specific. The expression 
of sLex in adult T cell leukaemia cells is reported to be dependent on FucT-VII activity because the 
etiologic agent of this pathology (the human T-lymphotropic virus 1) encodes a transcriptional 
activator protein that regulates the transcription of FucT-VII (68). At the same time, in breast 
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tumour its expression is regulated by FucT-VI (69) and in lung cancer by a coordinate up-regulation 
of FucT-III and -VI (70). The antigen sLex is overexpressed also in colon cancer but the enzyme 
responsible for its biosynthesis, FucT-VI, does not result upregulated (71). The aberrant expression 
of sLex and sLea in gastric cancer has been associated with the activation of the β1,3GlcNAc 
transferase that is an upstream enzyme in their biosynthetic pathway (72). On the other hand, the 
low sLex expression in normal colonic mucosa is at least partially due to the concomitant high 
expression of the competing enzyme β4GalNAcT-II, synthesizing the Sda antigen (73).  
 
Fig. 1.7 Structure and biosynthesis of sialyl Lewis antigens and Sia6LacNAc. The binding of a β1,3 Gal to the GlcNAc 
forms the basic unit of the type 1 chain, while the binding of β1,4 Gal leads to the formation of lactosamine, the basic 
structure of type 2 chain. The addition of a α2,3 sialic acid to both chains operated by different sialyltransferases creates 
the substrate for the action of FucT-III or FucT-III, -IV, -V, -VI, -VII that form sialyl Lewisa or sialyl Lewisx, 
respectively. The lactosamine can also be elongated by the addition of a α2,6 sialic acid by ST6Gal-I, forming 
Sia6LacNAc (25). 
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1.3.5. Polysialic acids 
The increased level of sialylation in tumours can also be due to the expression of polysialic acids 
(polySia). They are long linear arrays of sialic acids linked with a α2,8 bond to N-linked chains. 
The enzymes involved in the biosynthesis of polysialic acids are ST8Sia-II and ST8Sia-IV (74). 
Recent studies report that the presence of polySia on N- and O-glycans are essentials for cell 
migration and plasticity during nervous system development (75, 76), for regeneration of damaged 
neurons (77) and for liver development and regeneration (78). In cancer, they are frequently 
expressed in high grade tumours (79) mainly from neuroectodermal origin (80) and are correlated 
with high aggressiveness and poor prognosis (81). 
 
1.3.6. Gangliosides 
Gangliosides are sialic acid-containing glycosphingolipids. Their biosynthesis starts in the cis 
Golgi by the enzymatic activity of ST3Gal-V, ST8Sia-I and ST8Sia-V that show high specificity 
towards glycolipids (82). After the synthesis of the precursors, other glycosyltransferases can 
further elongate the chains by the addition of GalNAc, Gal or sialic acid in a stepwise manner (83). 
Gangliosides are often aberrantly expressed in tumours such as melanoma, neuroblastoma and 
breast cancer (84). In particular, the ganglioside GD3, highly expressed in cancer tissue (85), can 
promote tumour progression due to interaction with integrins (86), growth factor receptors (87, 88) 
and Src kinase (89). GD1α is reported to be a crucial mediator of breast cancer metastasis to the 
brain, because the aberrant expression of this antigen usually restricted to the brain enables breast 
cancer cells to pass through the blood-brain barrier (90). 
 
1.3.7. Sia6LacNAc 
The sialylated cancer-associated antigen that will be the focus of this work is Sia6LacNAc. It is 
synthetized by the enzyme β-galactoside α2,6 sialyltransferase (ST6Gal-I) by the transfer of a α2,6-
linked sialic acid to lactosaminic chains. It is recognized by the lectin Sambucus nigra (SNA) which 
has been widely used to detect the antigen in normal and cancer tissues (33, 91, 92). ST6Gal-I is 
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considered a cancer-associated glycosyltransferase, in fact its elevation was detected by our and 
other groups in colon cancer tissues (93-95), and confirmed in many other malignancies (24). It 
has been reported that SNA reactivity and ST6Gal-I expression in colon cancer is associated with 
poor prognosis (96, 97). Moreover, Gebert et al. reported that increased SNA reactivity was mainly 
associated with microsatellite stable (MSS) colon cancer phenotype (98). This is probably due to 
the fact that ST6Gal-I expression is regulated by Ras oncogene, which is commonly mutated in 
MSS colon cancer (refer to section 1.2.). In fact, it has been demonstrated that both oncogenic N-
ras and H-ras stimulate ST6Gal-I expression (99), and that Ras triggers β1-integrins sialylation 
through the overexpression of ST6Gal-I in a colonocyte cell line (100). 
A recently published study reported that ST6Gal-I is markedly upregulated in hepatocellular 
carcinoma tissue and cells. Moreover, its high values correlate with aggressiveness and poor 
prognosis (101). These findings agree with the elevated presence of ST6Gal-I in rodent hepatoma 
(102) but disagree with previous data showing that only a small group of liver cancer patients 
displayed increased ST6Gal-I expression (103). Moreover, in prostate cancer tissues ST6Gal-I 
expression was higher compared to normal prostate tissue. In fact, high ST6Gal-I expression 
positively correlated with Gleason scores, seminal vesicle involvement and poor survival (104). In 
vitro, the overexpression of ST6Gal-I promoted cell proliferation, migration and invasion in cell 
lines from hepatocellular carcinoma (101), pancreatic ductal adenocarcinoma (105), prostate 
cancer (104) and osteosarcoma (106). Previous studies demonstrated that ST6Gal-I is responsible 
for the α2,6-sialylation of β1-integrins resulting in increased binding to extracellular matrix in 
epithelial cancers (100, 107-110) and in integrin-based signal transduction (focal adhesion kinase 
signalling) providing survival signals. Moreover, α2,6 sialylated β1-integrins can reduce the 
binding of galectin-3 (111) a lectin that can have a pro-apoptotic effect (112), inhibiting apoptotic 
death and, thus, increasing malignancy. On the other hand, ST6Gal-I expression in the colon cancer 
cell line SW948 reduced its tumorigenic potential and its multilayer growth (109), its expression 
reduced also the invasive growth of glioma cells (113-116). Moreover, loss of ST6Gal-I, due to 
epigenetic regulation of the promoter, reduced invasiveness in prostate cancer tissues (117). In 
addition, St6gal1-null mice present normal development and defects mainly in IgM production 
(118) and granulopoiesis (119). Mammary tumours developed by St6gal1-null mice displayed 
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higher differentiation, but the same growth rate and a selectively altered expression of genes 
associated with focal adhesion signalling with a reduced phosphorylation of focal adhesion kinase, 
compared with the wild-type (120). Interestingly, the α2,6-sialylation of VEGFR (vascular 
endothelial growth factor receptor) prevented angiogenesis and tumour progression. In hypoxic 
conditions ST6Gal-I was downregulated while MGAT5 was upregulated, this leads to an altered 
expression of the N-linked glycans on VEGFR2 and consequent binding to galectin 1 activating 
vascular endothelial growth factor (VEGF) signalling (121). More importantly, ST6Gal-I 
expression is associated with resistance to radiations and drugs. In fact, it has been reported that 
ST6Gal-I confers cisplatin resistance to ovarian cancer cells (122), multidrug resistance in 
leukaemia cells (123) and resistance to gefitinib resistance in a colon cancer cell line due to 
sialylation of the receptor (124). However, in human T lymphoblastic leukaemia cells the resistance 
to desoxyepothilone B correlates with reduced expression of ST6Gal-I (125). In addition, ST6Gal-
I is involved in resistance to radiations as the exposure to ionizing radiation resulted in higher 
expression of the enzyme in animal models and cell lines (126), while the overexpression of 
ST6Gal-I in colon cancer cells results in radiation resistance (127).   
 
1.4. APOPTOSIS 
Apoptosis is a programmed pathway for cell death and occurs in many tissues of the body to 
maintain homeostasis. It is well known that the impairment of the apoptotic machinery is a hallmark 
of malignancy giving the cancer cells the ability to survive with severe damages to their DNA 
(128). Apoptosis occurs through two different pathways: the intrinsic and the extrinsic pathway. 
The intrinsic pathway is characterised by the release of cytochrome c and Smac/DIABLO (second 
mitochondrial activator of caspases/direct IAP-binding protein with low pI) from the mitochondria 
into the cytoplasm (129). This follows the mitochondrial outer membrane permeabilization 
(MOMP) which is controlled by stress sensor that alters the interactions of the Bcl-2 proteins (B-
cell lymphoma 2) (130).  The BH3-only proapoptotic proteins (part of the Bcl-2 family) promote 
Bax and Bak oligomerization at the mitochondrial outer membrane inducing MOMP. In the 
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cytoplasm, cytochrome c triggers  the assembly of the apoptosome complex containing the 
initiating caspase-9 that is able to activate the effector caspases (129). 
The extrinsic apoptosis pathway involves the binding of death ligands on death receptors on the 
surface of the cell and the transmission of the signal to the effector caspases (131). The most studied 
family of death ligands is the tumour necrosis factor (TNF) family which includes TNF, Fas ligand 
(FasL), and TRAIL (TNF-related apoptosis-inducing ligand). The binding with the death ligand 
triggers death receptor trimerization and the formation of the death-inducing signalling complex 
(DISC) with subsequent activation of the initiator caspase-8 and the effector caspase-3 (131). Both 
these pathways result in the typical phenotype of apoptotic cells which consist in plasma membrane 
“blebbing,” cell shrinkage, chromatin condensation, and internucleosomal DNA fragmentation 
(131).  
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Fig. 1.8 Extrinsic and Intrinsic pathways of apoptosis. The extrinsic pathway starts with the binding of death ligands 
(TNF, TRAIL, FASL) to death receptors. Then, receptor oligomerisation and formation of the DISC (death induced 
signalling complex) triggers the activation of the initiator caspase-8 and the effector caspase-3. In the intrinsic pathway 
the stress sensor proteins BH3-only (part of the Bcl-2 family) promote Bax and Bak oligomerization at the 
mitochondrial outer membrane inducing permeabilization (MOMP) and release of cytochrome c and Smac/DIABLO 
that activates the initiating caspase-9 and the effector caspase-3/7 (132). 
 
1.4.1. ST6Gal-I and apoptosis 
According to some studies, ST6Gal-I could have a role in protection from apoptosis. In fact, it is 
known that in colon tumours β1-integrin is a substrate for the enzyme ST6Gal-I and therefore 
presents α2,6-linked sialic acid at the end of its glycans (100). Secreted galectin-3, a tumour-
associated lectin, induces apoptosis via the binding with β1-integrin. However, sialylated β1-
integrin by ST6Gal-I impairs galectin-3 binding and therefore protects from apoptosis (133). 
Moreover, ST6Gal-I can shield the cells from apoptosis also by sialylation of death receptors. In 
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fact, the α2,6-sialylation of the tumour necrosis factor receptor 1 (TNFR1) in macrophages impairs 
TNFα induced apoptosis (134). In addition, Fas death receptor sialylation by ST6Gal-I confers 
protection against Fas-mediated apoptosis, therefore promoting tumour cell survival (135). 
A very recent study reported that ST6Gal-I could protect tumour cells against serum growth factor 
withdrawal. In fact, it shows that in ovarian and pancreatic cancer cell lines the overexpression of 
ST6Gal-I induces the activation of pro-survival signalling molecules, pNFκB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) and its tumour-promoting transcriptional factors, 
and the apoptosis inhibitor cIAP2. Therefore, this could increase tumour cells survival in a 
microenvironment depleted of growth factors (136).  
 
1.5. GROWTH FACTOR RECEPTORS 
Growth factor receptors are transmembrane proteins with an extracellular portion that binds growth 
factors and a cytoplasmic portion conveying the signal. Many of these receptors are tyrosine kinase 
receptors (TKRs) that dimerize after binding their ligand and trigger the signal through 
autophosphorylation of tyrosine residues in their cytoplasmic portion. They are often aberrantly 
expressed or activated in cancer, providing the cells with proliferative signals (128). Glycosylation 
plays an important role in growth factor receptors turn-over and activity. In fact, the presence of 
particular oligosaccharide chains can alter the binding between the receptor and the ligand and in 
general the signalling of the receptor (137, 138). Moreover, galectins can bind the glycans present 
on growth factor receptors and form a lattice that can control the receptors’ turn-over on the plasma 
membrane usually potentiating their signalling (139).  
 
1.5.1. HGF receptor 
Hepatocyte growth factor (HGF) receptor, also known as c-Met, is a heavily glycosylated 
transmembrane protein, which is expressed on epithelial cells of many organs including liver, 
pancreas, kidney and prostate (140). It is present also in normal colon, but its expression 
significantly increases in malignant tissue (141). C-Met receptor is composed of an extracellular 
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portion with three domains, one transmembrane helix and the catalytic domain in the cytoplasmic 
portion (Fig. 1.9). The α- and β-subunits form the Semaphorin (Sema) domain on the extracellular 
portion, which binds HGF and is necessary for receptor dimerization (142). Below, is localized the 
PSI domain responsible for the correct positioning of the ligand-binding site of the receptor (143). 
This domain is connected with the underlying transmembrane domain through the four 
immunoglobulin-plexin-transcription (IPT) domains. Intracellularly, the receptor is comprised of 
a tyrosine kinase catalytic domain, containing the catalytic tyrosines, and of a docking site that 
binds to signalling effectors (140). 
Upon HGF binding, the receptor undergoes homodimerization and autophosphorylation of the two 
tyrosines in the catalytic domain followed by the phosphorylation of the tyrosines on the C-terminal 
tail. This recruits effector proteins such as the adaptor protein GRB2 associated binding protein 1 
(GAB1), the growth factor receptor bound protein 2 (GRB2) and Src homology-2-containing 
(SHC), the effector molecules phosphatidylinositol 3-kinase (PI3K), and v-src sarcoma viral 
oncogene homolog (SRC), and transcription factor signal transducer and activator of transcription 
(STAT-3). These effector proteins could propagate the signal through different pathways (140). 
The mitogen activated protein kinase (MAPK) pathway is activated via rat sarcoma viral oncogene 
homolog (RAS) and Son of Sevenless (SOS) signalling resulting in cell proliferation (144). 
Furthermore, c-Met signalling activates PI3K/Akt pathway inducing cell survival and resistance to 
apoptosis (145). Another signalling pathway activated by HGF receptor is the one leading to cell 
transformation. This pathway involves the phosphorylation of Janus kinase 1 (JNK), via binding 
to CRK (146), and STAT3 (signal transducers and activator of transcription 3) (147).On the other 
hand, cell migration is promoted downstream c-Met by the focal adhesion kinase (FAK) through 
the phosphorylation of Src, in this way the cell acquires the ability to growth in absence of 
anchorage (148). FAK is localized at cellular adhesion complexes and is associated with integrin 
related signalling, therefore playing an important role in cellular migration and adhesion (149). 
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Fig. 1.9 c-MET signalling pathway. HGF binding triggers receptor dimerization and autophosphorylation of the 
tyrosines within the multifunctional docking site. They recruit signalling effectors and adaptor proteins such as GRB2, 
SHC, CRK and CRK-like, PI3K, PLCγ1, SRC, STAT3. In addition, GAB1, a multi-adaptor protein, can bind directly 
to c-MET or through GRB2. c-MET signalling activates the MAPK cascade through the activation of RAS via binding 
with SHC and GRB2. The activation of this pathway leads to cell proliferation, cell motility and cell cycle progression. 
Also SHP2, which is recruited by GAB1 to the receptor, can activate the MAPK pathway. PI3K can bind directly to 
the receptor or via GAB1 and activated the AKT/protein kinase B pathway leading to cell survival response. The 
transformation signalling of c-MET is mediated by phosphorylation of JNK, which occurs via binding to CRK and 
STAT3. The direct binding of STAT3 to the receptor cause SAT3 phosphorylation, dimerization and translocation to 
the nucleus where it promotes the transcription of genes involved in tubulogenesis and invasion. c-MET through the 
direct binding of SRC kinase activated FAK signalling resulting in cell migration. Adapted from Organ et al. 2011  
(140). 
 
1.5.2. EGF receptor 
Epidermal growth factor (EGF) receptor ErbB-1 is part of the ErbB (erythroblastic leukaemia viral 
oncogene homolog) family which is comprised also by ErbB-2, ErbB-3 and ErbB-4. Their structure 
is similar and consists of an heavily glycosylated extracellular portion containing the ligand-
binding domain, a single transmembrane helix and a cytoplasmic portion comprising the catalytic 
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domain (150). The extracellular portion of ErbB1 is composed of three domains: domain 1 and 3 
recognize the ligand and domain 2 is necessary for dimerization (151). The intracellular portion 
contains a juxtamembrane (JM) segment, a protein kinase domain, and a carboxy-terminal tail 
(152). EGF binding triggers receptor homo or heterodimerization, in particular ErbB-1 interacts 
with ErbB-2, resulting in kinase activation through transphosphorylation (150). The binding to the 
terminal tail by Grb2, SOS or by the adaptor molecule Shc activates the MAPK pathway via Ras, 
resulting in the activation of transcription factors involved in cell proliferation. Moreover, the PLCγ 
interacts with the receptor and catalyses the hydrolysis of phosphatidylinositol 4,5-diphosphate to 
inositol 1,4,5-triphosphate, that releases intracellular calcium, and 1,2-diacylglycerol that activates 
protein kinase C (PKC) signalling pathway, resulting in MAPK and c-Jun pathway activation 
(153). On the other hand, the dimerization of EGFR and ErbB-3 allows the direct binding of PI3K 
to the phosphorylated tyrosines of the receptors’ tail. This activates the PI3K/Akt pathway involved 
in cell survival, invasion, migration and resistance to apoptosis (154). In addition, also STAT 
proteins bind to EGFR and, after their dimerization, translocate to the nucleus and promote the 
expression of specific target genes (153). Another signal transducer that binds to EGF receptor is 
Src that activates FAK, PI3K and STAT regulating cell proliferation, migration and adhesion (155). 
EGF receptor can be internalized via endocytosis resulting in receptor degradation, recycling or 
nuclear translocation contributing to signalling. In the nucleus EGFR can induce DNA replication, 
DNA damage repair, transcription and cell proliferation because of the gene transactivation activity 
at the C-terminal portion (154). In particular, nuclear EGFR binds to the promoter of the cyclin D1 
gene (CCND1) increasing its transcription (154). EGFR can also behave as a cofactor for STAT3 
and E2F1 transcription factors (153). Other target genes for nuclear EGFR are NOS2 (inducible 
nitric oxide synthase), which catalyse the formation of nitric oxide necessary for inflammation 
signalling; AURKA (Estrogen-Induced Aurora Kinase-A), a protein kinase associated with 
microtubules, and the transcription factor BMYB (B-myeloblastosis virus), responsible for cell 
differentiation, proliferation and survival (156).  
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Fig. 1.10 EGFR signalling pathway. EGF binding cause receptor homo/heterodimerization and to phosphorylation of 
specific tyrosine residues. This recruits to the receptor several effector proteins such as PLCγ, STAT and PI3K, or 
adaptors as Shc, GRB2. Their activation results in the signalling through PKC, AKT and MAPK pathways that induce 
cell proliferation and survival, and through FAK pathway that cause cell migration. EGFR can also be internalized by 
endocytosis and can either behave as a transcription factor or as a co-regulator of other gene transactivators. Both 
pathways result in transcription of genes involved in cell proliferation, survival, invasion and metastasis. Adapted from 
Scaltriti et al. 2006(153). 
 
1.5.3. ST6Gal-I and growth factor receptors 
Among the glycosyltransferases that can act on growth factor receptors, ST6Gal-I plays an 
important role on receptor activation and can exert an inhibitory or activator effect. In fact, it has 
been reported that sialylation of EGFR in colon cancer cells reduces the receptor activation due to 
EGF binding, but in contrast it decreases the cytotoxic effect of gefitinib, therefore inducing 
resistance to chemotherapy (157). Moreover, in lung cancer cells the overexpression of ST6Gal-I 
suppresses EGFR dimerization and phosphorylation upon EGF treatment, reducing EGFR-
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mediated invasion (158). On the other hand, sialylation of EGFR could enhance EGFR sensitivity 
to tyrosine kinase inhibitors (TKIs) in lung cancer cell lines (159). Furthermore, sialylation of the 
VEGFR operated by ST6Gal-I prevents galectin 1 binding and VEGF-signalling, resulting in anti-
VEGF drug sensitivity (160). However, ST6Gal-I exerts an activator effect on the hepatocyte 
growth factor receptor (c-Met). In fact, in a colon cancer cell line, the knockdown of ST6Gal-I 
induces hyposialylation of c-Met and reduces cell motility (161). Moreover, in a breast cancer cell 
line the overexpression of ST6Gal-I promotes TGFβ-induced epithelial to mesenchymal transition 
(EMT) and the maintenance of the mesenchymal state, which can promote malignant progression 
(162). 
 
1.6. CANCER STEM CELLS AND PLURIPOTENCY 
Stem cells are defined as a population of cells able to self-renew indefinitely, form single cell 
derived populations and differentiate into various cell types (163). Stem cells found in human 
tissues are generally multipotent and can originate a restrict number of cell types unlike embryonic 
stem cells (ESCs) that are pluripotent and can originate any cell type. Recently, great emphasis has 
been given to the discovery that somatic cell can undergo de-differentiation through the expression 
of specific transcription factors such as Oct4 (octamer-binding transcription factor 4), SOX2 (sex 
determining region Y box 2), c-Myc and KLF4 (Kruppel-like factor 4) (164). These reprogrammed 
cells have been called induced pluripotent stem cells (iPSC) and share many characteristics with 
ESCs but present also differences (165), for example different DNA methylation (166). Stem cells 
have been recognized also in cancer tissues where they acquire the ability to survive from 
conventional treatment and escape from the immune system (167). Therefore, they can cause 
recurrence of cancer because even few surviving cancer stem cells (CSC) are sufficient to form a 
new tumour (168). At present, the mechanism of CSC development is still controversial. One 
theory suggests that they can be due to oncogenic mutations accumulating within adult stem cells, 
which leads to their uncontrolled proliferation, retaining stemness. The second theory considers 
cellular dedifferentiation from a cancer cell into a stem-like state (169). Regardless the mechanism 
of development, markers have been identified to recognise cancer stem cells. In particular, in colon 
cancer Oct4, SOX2, c-Myc, and KLF4 (that can dedifferentiate cells in iPSC) together with 
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NANOG (Homeobox protein NANOG) are overexpressed, conferring the cells a stem cell like 
phenotype (170). Other most used markers for CSC identification are CD133 and CD44. CD133 is 
a well-known stem cell marker and it has been reported that cells CD133+ isolated from primary 
CRC were able to originate tumours in mice (171). CD44 is overexpressed since early events of 
colorectal cancer development because its expression is regulated by the Wnt pathway, often 
altered in CRC (172), single CD44+ cells are able to form tumour spheres with stem cell 
characteristics that give rise to tumours when injected in mice (172). There are other markers under 
study for the identification of colorectal CSCs. SALL4 (Sal-like protein 4) controls self-renewal 
and pluripotency in embryonic stem cells, evidences suggest that it is regulated by the Wnt pathway 
(173); moreover, it has been found in plasma of patients with local CRC (174). ABCG2 is part of 
ATP binding cassette superfamily, therefore involved in drug resistance (175), and is associated 
with proliferation and maintenance of CSCs, as well as tumour formation (176). STAT3 is a 
transcription factor correlated with increased proliferation and invasion of cancer cells (177), its 
presence has been reported in tumour-initiating CD133+ cells (178). In addition, other potential 
markers that can be used to identify CSCs are EpCAM and LGR5. EpCAM (Epithelial cell 
adhesion molecule) is principally expressed on tumours of epithelial origin and is enriched in colon 
tumours relative to normal colon. EpCAMHigh/CD44+cells can originate tumours if injected in mice 
(179). LGR5 (Leucine-rich repeat-containing G-protein coupled receptor 5) is a newly identified 
marker whose knockdown causes tumour regression, while its recovery induces tumour growth 
and recurrence (180). Finally, aldehyde dehydrogenase 1 (ALDH) is considered a typical marker 
of normal and cancer stem cells. Its expression is increased in CRC correlating with poor prognosis. 
In fact, ALDHHigh cells display properties of CSCs, such as self-renewal, in vivo tumour growth 
potential and chemoresistance (181). Moreover, it has been reported that patients with high ALDH 
before chemoradiation present recurrence after surgery, thus ALDH can predict the prognosis of 
patients receiving post-surgery chemoradiation (182). 
 
1.6.1. ST6Gal-I involvement in cancer stem cells 
In the attempt of defying the phenotypic characteristics of iPSCs and CSCs, many studies have 
considered the role of glycans in these cell types because of their known functions in cell-cell 
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interactions in normal cell differentiation and embryogenesis. The glycomic analysis performed by 
Hasehira et al. (183) on iPSC highlights differences on the glycan profile between iPSC and 
somatic cells (SC). In fact, they report that upon induction of pluripotency high mannose-type N-
linked glycans increased and that α-1–2 fucose and Galβ1,3GlcNAc type 1 structures became 
evident. Moreover, they observed a shift from α2,3- to α2,6-linked sialic acid in iPSCs compared 
to SC. This correlates with data showing increased expression of ST6Gal-I obtained with 
microarray analysis. The increased expression of ST6Gal-I and thus the presence of α2,6-linked 
sialic acid in iPSCs was also confirmed in other studies (184, 185). In a more recent study it has 
been proposed that ST6Gal-I could contribute to the regulation of pluripotency (186). In fact, 
downregulation of ST6Gal-I induces a reduced Oct4 expression, significantly modulated the 
expression of genes involved in cell differentiation and impaired the induction of cellular 
pluripotency in somatic cells. In addition, ST6Gal-I colocalizes with ALDH staining at the base of 
crypts in colon normal tissue, or in the basal epidermal layers of the skin, where progenitor cells 
are found, and its expression is up-regulated in CSCs derived from colon cancer cell lines 
ALDHHigh and CD133+ (187). Furthermore, the work of Schultz et al. points out that the 
downregulation of ST6Gal-I in pancreatic and ovarian cancer cell lines impaired CSC spheroid 
formation, and that cells from primary ovarian cancer sorted for α2,6 sialylation were able to grow 
as spheroids in comparison with cells lacking α2,6 sialylation (188) confirming that this 
sialyltransferase could induce a CSC state. 
 
1.7. PREVIOUS RESULTS 
In the literature it has been reported that ST6Gal-I activity and SNA reactivity increase in colon 
cancer specimen compared to normal mucosa. These data were first reported by our group (91, 93) 
and confirmed later by others (95). In particular, the enzymatic activity of ST6Gal-I in cancer tissue 
was always higher than that of normal samples but the extent of its activation was different among 
patients (Fig. 1.11A) (189). Moreover, SNA reactivity to Sia6LacNAc was higher in colorectal 
cancer specimens (Fig. 1.11 B.1-B.4) but partially correlated with enzymatic activity data of 
corresponding samples. Real time PCR performed on normal and cancer tissues showed the 
presence of two ST6Gal-I transcripts, the housekeeping variant that present Y and Z exons, and the 
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hepatic form, the latter one increased in neoplastic tissue. Subsequent studies demonstrated that the 
expression of ST6Gal-I is controlled by Ras oncogene, explaining its upregulation in different types 
of cancer (99). On the other hand, studies performed on a colorectal cancer cell line (SW948) 
transfected with cDNA of rat ST6Gal-I indicated that the overexpression of the enzyme could 
attenuate the neoplastic phenotype of the cells (109). In fact, ST6Gal-I-transfected clones showed 
increased binding to collagen IV and fibronectin, compared to mock-transfected cells (Fig. 1.11 
C.1-C.4). This was probably due to the increased level of expression of β1-integrins, often reported 
as substrate for this enzyme. In addition, when ST6Gal-I-transfected and mock-transfected cells 
were mixed and injected together in nude mice, only mock cells were able to develop tumours (Fig. 
1.11 D).      
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Fig. 1.11 Previous results obtained from our group. A: ST6Gal-I activity in normal (N) and tumour (T) tissue B: SNA 
staining of four histological section: B.1 normal colon tissue, B.2-B.4 colon cancer tissue. C Adhesion of untransfected 
SW948 (white), mock-transfected clones (grey) and ST6Gal-I transfected clones (black) to fibronectin (C.1), collagen 
IV (C.2) and hyaluronic acid (C.3). D ST6Gal-I transfected cell (948F4) and mock (948neo2-4) were mixed in the 
same number and injected together in mice. The genomic DNA was extracted from the tumour and amplified with a 
primer pair specific for the regions of the vector flanking the insert. In the tumours was present only an amplification 
product corresponding to the empty vector of the 948neo clones.   
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2. AIM OF THE PROJECT 
 
From the literature and from previous observations obtained by our group, it is evident that the 
sialyltransferase ST6Gal-I and its cognate antigen Sia6LacNAc are associated with cancer, but it 
is still unclear their role in tumour development and progression. This project is aimed to: 
a) elucidate possible correlations between the expression of ST6Gal-I mRNA and clinical data 
from The Cancer Genome Atlas (TCGA) database. This database contains mRNA 
expression values obtained from microarray and RNAseq experiments on cancer specimens 
and normal tissue together with clinical data such as survival, stage of the tumour, mutations 
and response to conventional treatment. 
b) Evaluate the impact of ST6Gal-I overexpression in two colon cancer cell lines, SW948 and 
SW48, representing chromosomal instability and microsatellite instability respectively. 
These cells have been transduced with the cDNA of ST6Gal-I, originating SW948 and 
SW48 ST, or with an empty vector resulting in SW948 and SW48 negative control (NC). 
In particular, we will investigate whether ST6Gal-I expression in our models can alter gene 
expression profiles and the typical hallmarks of cancer, such as anchorage independent 
growth, migration and invasion capacity, apoptosis and stemness.   
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3. MATERIALS AND METHODS 
 
3.1. TCGA DATABASE 
Data regarding gene expression and clinical information of 623 cancer and 51 normal tissues from 
a cohort of colorectal-adenocarcinoma patients were downloaded from TCGA database while data 
regarding mutations were downloaded from cBioPortal (190). Data of TCGA database were 
downloaded from http://firebrowse.org/ considering only the cohort of colon adenocarcinoma 
(COADREAD). We downloaded separately the file with clinical data and mRNA expression and 
we removed the genes with average expression lower than five. Finally, we matched the clinical 
information with the gene expression results. ST6Gal-I mRNA expression values were analysed in 
comparison with tumoural/normal status, stage of the tumour, the presence of MSI phenotype 
(MSI-high or -low), response to treatment, the histological type, survival, and with KRAS, BRAF, 
APC and TP53 mutations. The samples do not present a normal distribution; therefore, it has been 
necessary to use non-parametric tests. Mann Whitney test was used to analyse ST6Gal-I expression 
in tumoural/normal status, mucinous/non-mucinous histological type, and in correlation with 
KRAS, BRAF, APC or TP53 mutations. Kruskal-Wallis test was used to evaluate ST6Gal-I mRNA 
expression, with respect to cancer stages and presence of MSI phenotype. The survival curve was 
calculate using the Mantel-Cox test for log-rank.    
      
   
3.2. CELL CULTURES  
SW948 (ATCC® Number: CCL-237™) and SW48 (ATCC® Number: CCL-231™) cell line were 
cultured in Leibovitz's L-15 Medium supplemented with 10% fetal bovine serum (FBS), 1% L-
Glutamine and 1% Penicillin/Streptomycin. Cells were kept at 37°C in absence of CO2 (L-15 is 
phosphate buffered) in a humidified incubator.  
As reported in Malagolini et al. (191) SW948 ST and SW48 ST were transduced with the cDNA 
of the whole coding sequence of human ST6Gal-I obtained from Caco2 cells. The entire coding 
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sequence without 5’-untranslated regions (5’-UTR) was PCR amplified using the following primer 
pair: the forward primer (hST6Gal-I.L1) consisting of the nucleotide sequence 
CACCATGATTCACACCAACCTGAAGAAAAAGTTCAGCTGCTGC and the reverse primer 
(hST6Gal-I.R1) consisting  of the sequence  
TTAGCAGTGAATGGTCCGGAAGCCAGGCAGTGTG. The underlined sequence included in 
the forward primer is necessary for the directional cloning in the TOPO vectors and is not gene 
specific. The PCR product was cloned in the pLenti6/V5 directional TOPO vector (Invitrogen, 
Carlsbad, CA) and used to transfect the 293FT cell line, according to the instruction manual of the 
Vira Power Lentiviral Expression System (Invitrogen). The conditioned medium, containing the 
virions, was centrifuged to remove cell debris, filtered on a 0.45 µM membrane, diluted with 9 
volumes of fresh culture medium, added to SW948 cells, and left for 48 h. Cells were selected by 
the presence of 10 µg/mL blasticidin. A mock transduction was run in parallel with a lentivirus 
lacking the ST6Gal-I insert, originating SW948 and SW48 NC (Negative control) cells. 
 
3.2.1. Cell treatments 
Both apoptosis inducer and growth factors were added directly to the culture medium at a 
concentration determined as follows: 
- TPEN (N,N,N′,N′-Tetrakis(2-pyridylmethyl)ethylenediamine) is resuspended in water to a 
final stock concentration of 10 mM and used on cell at 10 µM. 
- Recombinant HGF (hepatocyte growth factor) is resuspended in PBS and bovine serum 
albumin (BSA) 0.1% to a final stock concentration of 10 µg/ml and used on cells at 25 ng/ml. 
- Recombinant EGF (epidermal growth factor) is reconstituted in water to a final stock 
concentration of 1 µg/µl and used on cells at 5 and 20 ng/ml. 
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3.2.2. Induction of apoptosis 
To evaluate the propensity of SW948 and SW48 NC and ST to undergo apoptosis through the 
intrinsic pathway, 2*106 SW48 or 1.5*106 SW948 cells were plated per well in a multiwell 6 plate. 
After 2 days they were treated with TPEN at a final concentration of 10 µM and collected at 
different time points by trypsinization or by direct lysis in the wells, depending on the downstream 
analysis.  
 
3.2.3. Treatment with HGF and EGF 
SW948 and SW48 NC and ST were plated respectively at a concentration of 2*106 and 1.5*106 per 
well in a multiwell 6 plate and they were let adhere for 24-48 hours. Then, they were starved in 
serum-free medium for 24 hours and treated with HGF or EGF at a final concentration of 25 ng/ml 
or 20ng/ml respectively, for 15, 30 minutes and 2 hours. The samples thus treated were collected 
by scraping the surface of the plate. 
 
3.3. ANALYSIS OF ST6Gal-I-TRANSDUCED CELLS 
 
3.3.1. Sample collection and cell lysis 
Cells were collected either by trypsinization or by scraping the surface of the plate. In the first case, 
cells were detached using trypsin and collected using complete L-15 to inactivate the enzyme. 
Then, the cells were centrifuged to collect the pellet, washed once with PBS, to remove any trace 
of serum and trypsin, and finally stored at -80°C as dry pellet until needed. The cells were then 
homogenized in water. 
In the second case, the cells were washed with PBS, lysed for 15 minutes in ice by directly adding 
the lysis buffer to the plate. The cells were then collected by scraping the plate surface, incubated 
in ice for 15 minutes and centrifuged for 20 minutes at 4°C at 10000xg. As lysis buffer we used 
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Ripa Buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 1%NP-40, 0.5% DOC, 0.1% SDS) 
supplemented with protease inhibitor and phosphatase inhibitor cocktail (100x). 
 
3.3.2. Determination of protein concentration 
Protein concentration was determined by using Lowry assay or Bradford assay. The sample 
concentration was calculated by interpolating the absorbance value to a standard curve obtained 
with known concentration of BSA. 
 
 
3.3.3. Western Blot 
Samples were prepared with an equal amount of proteins and made up to the desired loading 
volume by adding H2O and sample buffer 4x (0.5 M Tris HCl pH 6.8, 10% SDS, 30% Glycerol, 
6% β-Mercaptoethanol and 0.012% Bromophenol Blue), boiled for 5 minutes and separated in 8% 
to 12% acrylamide gel, depending on the molecular weight of the protein of interest in denaturing 
and reducing conditions. We used the PageRuler Prestained Protein Ladder as protein molecular 
weight markers. The proteins were then transferred to an activated PVDF membrane for 10 minutes 
using the BioRad Transblot turbo system.  
After the transfer, membranes were incubated for 1 hour at room temperature with 1-2% BSA in 
TBS-T (tris-buffered saline and 0,05%Tween20) as blocking solution, then incubated overnight at 
4°C with primary antibody on an orbital shaker. The following day, the membranes were washed 
with TBS-T and incubated for 1 hour at room temperature with a secondary antibody conjugated 
with Horseradish peroxidase (HRP). Detection was performed using Super Signal West pico as a 
chemiluminescent substrate. Pictures of the films were taken using EDAS 290 camera (Kodak). 
Densitometric analysis was performed using Kodak 1D software and statistical analysis with two-
way ANOVA followed by Holm-Sidak's multiple comparisons test. 
The following primary antibodies were used in Western Blots: mouse monoclonal anti-
phosphotyrosine (Cytoskeleton) and anti-vinculin (Sigma), rabbit polyclonal anti-β-Actin (Sigma) 
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and anti-FAK [pY397] (Life Technologies), goat polyclonal anti-ST6Gal-I (R&D systems). As 
secondary antibodies, polyclonal rabbit anti-mouse (Sigma), goat anti-rabbit (Sigma) and donkey 
anti-goat (R&D system) conjugated to HRP were used. To evaluate apoptosis, we used Apoptosis 
Western Blot Cocktail (pro/p17-caspase 3, cleaved-PARP, muscle Actin) (abcam). Both primary 
and secondary antibodies were diluted in TBS-T 0.05% + 0.1% BSA. 
  
3.3.4. Stress and apoptosis pathway protein array 
To evaluate apoptosis with the PathScan® Stress and Apoptosis Signaling Antibody Array Kit 
(Cell Signaling), SW948 and SW48 NC and ST were plated respectively at a concentration of 
2*106 and 1.5*106 per well in a multiwell 6 plate and they were let adhere for 24-48 hours. They 
were treated with TPEN 10 µM at different time points and lysed directly on the plate with the lysis 
buffer of the kit following manufacturer’s instructions. Protein concentration was measured as 
previously described with Bradford assay. 50 µl of cell lysates were then incubated for 2 hours on 
the slide at a final concentration of 1 mg/ml after blocking the non-specific sites with Array 
Blocking Buffer. The slide was washed with Array Wash Buffer and incubated with the Detection 
Antibody Cocktail for 1 hour. Then, it was washed again and incubated for 1 hour with HRP-linked 
Streptavidin and the chemiluminescent signal was obtained by incubation of the slide with 
LumiGLO and Peroxide and read through a ChemiDoc Imaging System (BioRad). 
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Fig. 3.1 Target map of the PathScan® Stress and Apoptosis Signaling Antibody Array Kit (Chemiluminescent Readout) 
#12856. 
 
3.3.5. Sialyltransferase activity 
Sialyltransferase activity was measured in whole cell homogenate by incorporation of [3H] sialic 
acid on asialotransferrin. Radioactivity incorporated on endogenous acceptors was subtracted. A 
solution containing 80mM Na-cacodylate buffer pH 6.5 and 0.5% Triton X-100 was incubated with 
300 µg asialotransferrin, 30 µM CMP-sialic acid, 1 µl CMP-[3H] sialic acid (1x105 dpm/µl) and 
100 µg of cell homogenate in a final volume of 50 µl for 3 hours at 37°C. After incubation the 
reaction was stopped by adding 500 µl of phosphotungstic acid (FTA) (1% phosphotungstic acid 
in 0.5 M HCl) and then washed twice with FTA. Then, the samples were boiled for 20 minutes 
with 300 µl of 1 M HCl. After the addition of 3.5 ml of liquid scintillation cocktail, the radioactivity 
of the samples was determined with the Guardian 1414 Liquid Scintillation Counter (PerkinElmer). 
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3.3.6. Evaluation of SNA reactivity 
Flow cytometry (FACS) analysis 
Approximately 5x105 SW948 and SW48 NC and ST cells were washed with PBS containing 1 
mg/ml BSA and incubated 20 minutes with 50 μg/ml FITC-conjugated SNA at 4°C in the dark. 
The samples were then washed with PBS/BSA and then resuspended with 500 µl of PBS 
supplemented with 2% formaldehyde. The analysis was performed using FACSCalibur (BD) and 
CellQuest Pro software (BD), the fluorophore was read with FL1 channel. 
Immunofluorescence 
A number of 8x105 SW948 and SW48 NC and ST cells were plated on a glass coverslip and let 
adhere for 24-48 hours. The coverslips were washed in PBS and then fixed with 2% formaldehyde 
for 20 minutes and then stained with FITC-conjugated SNA lectin for 20 minutes. After staining, 
they were washed and mounted on microscope slides. Images were taken with a Nikon Eclipse 
E600 microscope and DXM1200F digital camera.      
 
3.3.7. RNA extraction and cDNA reverse transcription 
Total RNA was extracted according to Chomczynski e Sacchi (192) and suspended in 50 µl of 
RNase free water. RNA concentration was determined using the Nano Genius Photometer ONDA, 
measuring absorbance at 260 nm with a 260:280 ratio of 2.1+/-0.5. RNA integrity was determined 
running RNA samples on a 1% agarose gel.  
RNA samples were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) following manufacturer’s instructions. 
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3.3.8. Transcriptomic analysis 
Transcriptomic analysis of RNA extracted from SW948 and SW48 NC and ST was carried out in 
duplicate at LTTA Microarray Facility, Università di Ferrara with Agilent Technologies. Statistical 
analysis was performed using two-way ANOVA for repeated measures and the false discovery rate 
was controlled with two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli with 
Q=0.05. P values and q values are listed in table 4.1 and 4.2. 
 
3.3.9. Real-Time PCR 
Real time PCR was carried out in triplicate using SsoAdvanced™ Universal SYBR® Green 
Supermix (BioRad) containing the fluorescent SYBR Green reagents, nucleotide mix and Sso7d 
fusion protein polymerase. To this mix, forward/reverse primers (details can be found in Table 1) 
at a concentration of 0.25 µM and sample cDNA (20ng) were added forming a total reaction 
volume of 10µl. The PCR reaction was carried out with a CFX96 machine (BioRad), using the 
following protocol: 98°C hold step for 2 minutes and 40 cycles of 98-60°C for 5 and 30 seconds 
respectively. 
Gene Forward 5’-3’ Reverse 5’-3’ 
ΒACT GCGAGCACAGAGCCTCGCCTTT GCACATGCCGGAGCCGTTGTCG 
KLK6 ACCTGGTGTCCCGTGAGGAGT CCACATACCAGCGGACCCCC 
MYEOV CATACACCCCAGCTCTCCCGA GCAACGAGTCCCTGTCCCCA 
OLFM4 GGCTTCAGCTCTTTCCCAGGTGT GGTCCCACGGTCATCCACGG 
TGFB2 CGCGAGAGGAGCGACGAAGA AGAAAGTGGGCGGGATGGCA 
FOLR1 ATGGCACCTGCCTGCAAACG GGGCACGTTCAGTACCCGCT 
SH3GL2 CGGCCTCAAGAAGCAGTTCCAT GCCCTGCTGGTGACATCCACTTTC 
FMOD CCCCCAGTCAACACCAACCTGG ACGTCCACCACGGTGCAGAA 
MAP1B TCAAAGCTGCACGTGGGGAAGA CCTGGGGGCACAGCAGATGAC 
MT4 GGACCCCAGGGAATGTGTCTGC CCCCGGGCACATTTGGCACA 
WNT16 TCGGAAACACCACGGGCAAAGA GGAGCCGGAAACTCCGTGGC 
Table 3.1 Primers’ sequences. 
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To evaluate ST6Gal-I mRNA expression in SW948 and SW48 transduced cells we performed real 
time PCR in triplicate with TaqMan® Fast Universal PCR Master Mix (Applied Biosystems) 
supplemented with the sample (20 ng) and TaqMan probes and primers for ST6Gal-I (assay 
identification Hs00949382_m1) or β-ACTIN (Hs99999903_m1) in a final volume of 10 µl. The 
reaction was conducted with the same protocol used for SYBR® Green real time PCR.   
 
3.3.10. Soft agar growth assay  
A 3,3% solution of agar in water was diluted to a final concentration of 0,5% in complete L-15. 1 
ml of this solution was dispensed per well in a multiwell 6 plate. On the top of this first layer of 
agar we distributed a 0.3% agar solution in complete L-15 medium, containing 1 x104 cells per well 
in triplicate. The plates were then incubated for two weeks at 37°C in a humidified incubator 
without CO2. To evaluate the number of colonies formed, the plates were fixed and coloured for 
one hour with a solution containing formaldehyde 4% and Crystal Violet 0.005% in PBS. Pictures 
were taken using a Nikon Eclipse TS100 inverted microscopy a 5x magnification and a Digital C-
Mount camera Sony Colour. Then the colonies were counted, and statistical analysis was performed 
using non-parametric Kolmogorov-Smirnov test.  
 
3.3.11. Wound healing assay  
 The wound healing assay was performed using Culture-Insert 2 Well (Ibidi). This consists in a 2 
well silicone insert with a defined cell-free gap which gives the possibility to plate the cells in the 
two wells and to evaluate their ability to close the wound once the insert has been removed. We 
prepared a solution with 1x106 cells/ml, in case of SW48, and 7x105 cells/ml, in case of SW948, in 
complete medium and plated 70 µl per well. When the cells reached confluency, we removed the 
insert and evaluated the capacity to migrate taking pictures with Nikon Eclipse TS100 inverted 
microscopy a 10x magnification and a Digital C-Mount camera Sony Colour. The area was then 
measured using the MRI Wound Healing Tool in ImageJ. Statistical analysis was performed using 
two-way ANOVA and Tukey's multiple comparisons test. 
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3.3.12. Transwell invasion assay 
The transwell invasion assay was performed using Matrigel-coated polycarbonate filters (8 mm 
pore size, Corning BioCoat Matrigel Invasion Chamber). 3x106 SW948 cells were plated in T25 
flasks, while 5x106 SW48 cells were plated in T75 flasks and starved for 24 hours. Then they were 
detached and plated at a density of 2x105 for SW948 and 4x105 for SW48 in the upper chamber of 
the well in serum-free medium. Complete L-15 with 10% FBS or serum-free L-15 + HGF 25ng/ml 
were used as chemoattractant and placed in the lower chamber of the well. The plates were then 
incubated for 24 hours at 37°C in a humidified incubator without CO2. Following manufacturers’ 
instructions, the membranes were fixed in methanol and stained with toluidine blue. Finally, they 
were mounted on slides and the cells were counted using an optical microscope at a 10x 
magnification. Statistical analysis was performed using two-way ANOVA and Sidak's multiple 
comparisons test. 
 
3.3.13. ALDEFLUOR assay 
For the ALDEFLUOR (Stem Cell technologies) assay for stemness, we activated ALDEFLUOR 
following manufacturer’s instructions. For the samples preparation, the cells were detached with 
trypsin, counted using a Neubauer Chamber and collected in order to have 2x105 cells/ml per 
sample. Then we added ALDEFLUOR to our samples and we transferred half of the cell suspension 
to the tube containing DEAB, a specific ALDH inhibitor used for negative control. The samples 
were then incubated for 30 minutes at 37°C and centrifuged at 250 x g. Cell pellets were then 
suspended in ALDEFLUOR buffer. For the acquisition of the fluorescent signal we used a 
FACSCalibur and CellQuest Pro software. We opened a dot plot with the physical parameters and 
a second one representing FL1 (green fluorescence) on the X axis and SSC on the Y axis. On this 
second dot plot we set the fluorescence of the DEAB sample and defined the area for ALDH 
positive cells, then we acquired the sample with ALDEFLUOR reagent. Cells beyond the threshold 
established with DEAB sample were considered ALDEFLUOR positive.  
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3.3.14. Statistical analysis  
The GraphPad Prism 7 software was used to perform statistical analysis, using the different tests 
described above.    
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4. RESULTS 
 
4.1. THE IMPACT OF ST6Gal-I EXPRESSION ON THE PROGRESSION OF 
CRC: A SURVEY OF THE TCGA DATABASE 
The Cancer Genome Atlas (TCGA) is a public database, which contains data obtained from a high 
number of cancer patients. From interrogation of this database, it is possible to correlate data on 
gene expression with clinical data. We evaluated the mRNA expression levels of ST6Gal-I in CRC 
specimens and normal tissues. We noticed that the gene expression level was relatively constant in 
normal tissues, whereas it was extremely variable among CRC specimens (Fig. 4.1A). Surprisingly, 
the median mRNA level of our gene of interest in cancer tissue was similar to that of normal tissue 
(Fig. 4.1B), in contrast with enzymatic activity data reporting higher ST6Gal-I activity in tumour 
tissue compared to normal tissue (93). The expression of ST6Gal-I in the cohorts of patients 
showing the 15% higher or 15% lower expression was correlated with clinical parameters. Low 
ST6Gal-I expression was correlated with high microsatellite instability (Msi-h) (Fig. 4.1D), 
mucinous phenotype (Fig. 4.1E) and BRAF mutations (Fig. 4.2B). On the other hand, no 
correlation was observed between ST6Gal-I expression and clinical stage (Fig. 4.1C), mutations in 
KRAS (Fig. 4.2A), APC (Fig. 4.2C) and TP53 (Fig. 4.2D), response to therapy (Fig. 4.1F) and 
overall survival (Fig. 1K). Collectively, these data are not consistent with a strong impact of 
ST6Gal-I level on the progression of CRC, as suggested by previous clinical and experimental data 
(refer to introduction). 
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Fig. 4.1 Data from TCGA database. Evaluation of ST6Gal-I mRNA in patients (A), and in cancer and normal tissue 
(B). Correlation of ST6Gal-I expression with tumour stage (C), microsatellite phenotype: microsatellite stable (Mss), 
low microsatellite instability (Msi-l) and high microsatellite instability (Msi-h) (D), mucinous or non-mucinous type 
(E) and with response to therapy (F).  
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Fig. 4.2 Data from TCGA database. ST6Gal-I expression in colorectal cancer is correlated with mutation in KRAS 
(A), BRAF (B) APC (C) and TP53 (D). E shows the survival curve for patients expressing high or low ST6Gal-I.  
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4.2. THE IMPACT OF ST6Gal-I EXPRESSION ON THE PHENOTYPE OF 
CRC CELL LINES 
 
4.2.1. SW948 and SW48 cell lines 
To fully understand the role of ST6Gal-I overexpression in colon cancer, we selected two colon 
cancer cell lines, SW948 and SW48. These cell lines lack ST6Gal-I expression and enzyme activity 
and, in addition, they represent the two principal ways of colorectal cancer pathogenesis: 
chromosomal instability, in case of SW948, and microsatellite instability, in case of SW48. The 
two cell lines had been previously transduced with a lentivirus containing the cDNA of ST6Gal-I, 
obtaining ST cells, or with an empty vector, resulting in negative control (NC) cells (191). A 
characterization of these cell lines with regard to ST6Gal-I expression is reported in Fig. 4.3.  By 
RT-PCR, we noticed a high expression of ST6Gal-I mRNA in both SW948 and SW48 ST cells 
compared with NC cells (Fig. 4.3A). In addition, we analysed protein expression in western blot 
and we observed the presence of ST6Gal-I band only in transduced cells and not in NC cells (Fig. 
4.3B). Then, we analysed the enzymatic activity measuring the incorporation of radioactive sialic 
acid on asialotransferrin and we registered a higher activity in both ST6Gal-I transduced cell lines 
compared to their negative control (Fig. 4.3C). We evaluated also SNA reactivity, both by 
immunofluorescence and FACS analysis and we confirmed that SW948 and SW48 ST cells were 
more reactive with the lectin compared to NC cells (Fig. 4.3D, E). 
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Fig. 4.3 Characterization of SW948 and SW48 transduced with ST6Gal-I. We evaluated ST6Gal-I mRNA expression 
(A), protein level (B) and enzymatic activity (C); and SNA reactivity in immunofluorescence (D) and FACS analysis 
(E).  
 
4.2.2. Transcriptomic analysis 
To investigate whether and how the overexpression of ST6Gal-I could modify the gene expression 
profile of the colorectal cancer cell lines that we use as models, we performed a microarray analysis 
using Agilent Technologies. Fig 4.4 shows scatter plots representing gene expression of the two 
cell lines transduced with ST6Gal-I compared to their negative control (NC). We noticed that the 
overexpression of ST6Gal-I caused a more pronounced modulation of the transcriptome in SW948 
cells than in SW48 cells. In particular, the number of modulated genes and the extent of their 
modulation was higher in SW948 than in SW48 cells. In table 4.1 and 4.2 we report the list of 
modulated genes in SW948 and SW48 cells, respectively. Surprisingly, none of the differentially 
expressed genes displayed the same behaviour in both cell lines.  
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Fig. 4.4 Transcriptomic analysis. The two scatter plots show the relative gene expression of SW948 ST and NC cells 
and of SW48 ST and NC cells.  
 
Gene Symbol ST - NC q value p value Gene Symbol ST - NC q value p value 
OLFM4 4.4 0.0009 <0.0001 C1orf229 -2.0 0.0372 0.0589 
DUSP5 3.9 0.0031 0.0003 TSPEAR-AS2 -2.0 0.0367 0.0573 
RYBP 3.9 0.0031 0.0003 FLNA -2.0 0.0364 0.0565 
SH3GL2 3.6 0.0071 0.0008 CDCA5 -2.0 0.0364 0.0561 
SLC1A3 3.5 0.0074 0.0009 KLK6 -2.0 0.0364 0.0553 
TCL6 3.4 0.0105 0.0016 POLH -2.0 0.0363 0.0535 
MYEOV 3.3 0.0118 0.0022 DSCR9 -2.0 0.0362 0.0525 
CAPSL 3.1 0.0144 0.0033 ATXN8OS -2.0 0.0362 0.0520 
ANKRD1 3.1 0.0147 0.0036 DSCAS -2.1 0.0362 0.0494 
REG1A 3.1 0.0164 0.0042 LOC389602 -2.1 0.0362 0.0489 
FLNC 3.0 0.0173 0.005 SIM1 -2.1 0.0362 0.0487 
LRRD1 3.0 0.0173 0.0054 CTF1 -2.1 0.0362 0.0458 
DPY19L2P1 3.0 0.0173 0.0055 LEP -2.1 0.0356 0.0431 
SLIT1-AS1 2.9 0.0175 0.006 lnc-IL37-1 -2.1 0.0356 0.0423 
SLC14A1 2.8 0.0208 0.0081 LINC01239 -2.1 0.0356 0.0417 
ZNF439 2.8 0.0208 0.0084 DLC1 -2.2 0.0356 0.0415 
BST2 2.8 0.0217 0.0092 lnc-SYT4-1 -2.2 0.0356 0.0407 
H2AFY2 2.7 0.0220 0.0102 lnc-CRYGS-1 -2.2 0.0356 0.0407 
SMAD5-AS1 2.7 0.0232 0.0115 LINC01431 -2.2 0.0356 0.0395 
MMP7 2.7 0.0232 0.0115 FAM230B -2.2 0.0356 0.0391 
CALD1 2.7 0.0233 0.0119 LINC00520 -2.2 0.0356 0.0380 
THEG 2.6 0.024 0.0133 TRAM1L1 -2.2 0.0356 0.0343 
47 
 
MIP 2.6 0.0248 0.0149 FGF13 -2.2 0.0356 0.0342 
CNTN5 2.6 0.0248 0.015 PPP1R17 -2.2 0.0356 0.0334 
GGNBP1 2.6 0.0248 0.0157 MBD2 -2.2 0.0356 0.0327 
PHACTR3 2.6 0.0248 0.0158 ZNF345 -2.3 0.0349 0.0281 
DQX1 2.6 0.0248 0.016 OTOP2 -2.3 0.0334 0.0242 
WFDC21P 2.5 0.0248 0.0162 WNT4 -2.4 0.0333 0.0234 
PLA2G3 2.5 0.0264 0.0176 IQCF3 -2.4 0.0248 0.0142 
TGFB2 2.4 0.0315 0.0215 AKT1S1 -2.6 0.0240 0.0133 
CCDC148 2.4 0.0333 0.0237 CXCL12 -2.6 0.0240 0.0131 
SULT1C2P1 2.3 0.0349 0.0264 TCAF2 -2.6 0.0220 0.0103 
PCDHGB1 2.3 0.0349 0.0268 MIR4500HG -2.7 0.0220 0.0099 
ORAOV1 2.3 0.0349 0.0276 KLK6 -2.7 0.0208 0.0086 
MEDAG 2.3 0.0349 0.0276 LINC00643 -2.8 0.0208 0.0085 
EVI2A 2.3 0.0349 0.0283 USP17L1 -2.8 0.0198 0.0070 
FAM229B 2.3 0.0354 0.0292 GNAT2 -2.9 0.0173 0.0057 
LOC100506175 2.3 0.0356 0.0313 FMOD -2.9 0.0173 0.0048 
ACE2 2.3 0.0356 0.0327 PLAC4 -3.0 0.0144 0.0033 
CACNA1C-AS4 2.2 0.0356 0.0349 HBB -3.1 0.0119 0.0024 
DMBT1 2.2 0.0356 0.0352 SPTB -3.2 0.0109 0.0019 
MAPT-AS1 2.2 0.0356 0.0354 FAM230A -3.3 0.0090 0.0013 
TIMP3 2.2 0.0356 0.0368 FAT3 -3.4 0.0013 <0.0001 
RIMS3 2.2 0.0356 0.0368 EML5 -4.2 0.0009 <0.0001 
LOC550113 2.2 0.0356 0.0382 EIF4G3 -4.4 0.0001 <0.0001 
C20orf85 2.2 0.0356 0.0388 lnc-MYB-1 -5.1 <0.0001 <0.0001 
ATP2B2 2.2 0.0356 0.0413 PEG3 -5.4 0.1476 0.0062 
LOC440300 2.2 0.0356 0.0414 
APOBEC3C 2.1 0.0356 0.0426 
EDA2R 2.1 0.0356 0.0427 
SEMA7A 2.1 0.0356 0.043 
BST2 2.1 0.0358 0.0437 
IFIT2 2.1 0.0362 0.0453 
MYBL1 2.1 0.0362 0.0453 
EPB41L3 2.1 0.0362 0.0480 
CELF4 2.1 0.0362 0.0480 
LOC100506974 2.1 0.0362 0.0486 
PRB2 2.1 0.0362 0.0496 
GGT8P 2.1 0.0362 0.0503 
GPR110 2.1 0.0362 0.0514 
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TGFB2-AS1 2.1 0.0362 0.0515 
IL4R 2.1 0.0362 0.0520 
PTAFR 2.1 0.0363 0.0537 
PRO1082 2.0 0.0364 0.0545 
LINC01234 2.0 0.0364 0.0560 
IL1RN 2.0 0.0393 0.0635 
FOLR1 2.0 0.0393 0.0636 
Table 4.1 List of genes up- or down-regulated in SW948 ST cells in comparison with NC cells. The table reports on 
the left hand-side genes up-regulated in SW948 ST, whereas on the right hand-side genes down-regulated in SW948 
ST cells.  
 
Gene Symbol ST - NC q value p value Gene Symbol ST - NC q value p value 
OVAAL 3.3 0.0176 0.0007 NME8 -2.0 0.0419 0.0399 
BPI 3.1 0.0176 0.0013 PROM2 -2.0 0.0419 0.0396 
GLDC 3.0 0.0183 0.0024 DACT1 -2.0 0.0419 0.0374 
SLC7A4 2.6 0.0339 0.0080 ITGBL1 -2.0 0.0419 0.0366 
HRCT1 2.5 0.0339 0.0107 DCLK3 -2.0 0.0419 0.0362 
ATP6V0E2-AS1 2.4 0.0339 0.0120 IGFL4 -2.0 0.0419 0.0360 
MZF1-AS1 2.4 0.0339 0.0122 INSC -2.0 0.0419 0.0348 
FBXO3-AS1 2.3 0.0357 0.0159 NTRK2 -2.0 0.0413 0.0316 
CGA 2.3 0.0357 0.0165 RIMS2 -2.1 0.0413 0.0310 
CYS1 2.2 0.0357 0.0193 CALCA -2.1 0.0385 0.0273 
MASP2 2.2 0.0357 0.0207 ITGBL1 -2.1 0.0380 0.0263 
ATXN3 2.2 0.0360 0.0217 UGT2B7 -2.1 0.0373 0.0248 
F11 2.2 0.0360 0.0229 HILS1 -2.2 0.0360 0.0226 
ST3GAL4 2.1 0.0373 0.0251 lnc-WNT1-3 -2.2 0.0357 0.0205 
AMICA1 2.1 0.0408 0.0297 TSPAN3 -2.2 0.0357 0.0201 
MTUS2-AS1 2.0 0.0419 0.0333 KLHL14 -2.2 0.0357 0.0198 
MZB1 2.0 0.0419 0.0392 GALNT5 -2.2 0.0357 0.0198 
THTPA 2.0 0.0419 0.0399 PARP11 -2.3 0.0357 0.0181 
IGFL2 -2.3 0.0350 0.0144 
DOC2B -2.3 0.0350 0.0144 
ZGRF1 -2.4 0.0339 0.0127 
KRT14 -2.4 0.0339 0.0123 
C1QA -2.4 0.0339 0.0119 
ATRN -2.4 0.0339 0.0114 
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MAP1B -2.5 0.0339 0.0105 
NUDT12 -2.5 0.0339 0.0086 
SMIM22 -2.8 0.0230 0.0043 
CALCA -2.8 0.0230 0.0042 
PHGR1 -2.8 0.0230 0.0038 
WNT16 -3.0 0.0183 0.0024 
IFNA14 -3.0 0.0183 0.0019 
MT4 -3.2 0.0176 0.0011 
MAP1B -3.2 0.0176 0.0011 
Table 4.2 List of genes up- or down-regulated in SW48 ST cells in comparison with NC cells. The table reports on the 
left hand-side genes up-regulated in SW48 ST, whereas on the right hand-side genes down-regulated in SW48 ST 
cells.  
 
Considering the genes showing the stronger modulation, in SW948 the overexpression of ST6Gal-
I drives gene expression mainly towards up-regulation. In fact, we counted 67 up-regulated and 47 
down-regulated genes. Among them, we validated by RT-PCR seven genes with a potential role in 
tumour development or progression: OLFM4, SH3GL2, FOLR1, TGFB2, MYEOV, FMOD and 
KLK6 (Fig 4.5). We examined other genes potentially important in cancer biology, but the 
validation did not confirm their modulation.  
The more consistently up-regulated gene in SW948 ST cells resulted to be OLFM4 and its increase 
was confirmed also in RT-PCR. OLFM4 is a glycoprotein overexpressed in many tumours, 
including colorectal cancer, but its biological role seems to be strictly tissue specific (193). In mice, 
OLFM4 seems to regulate the Wnt/beta-catenin and NFκB pathways inhibiting colon-cancer 
development (194). Another highly modulated gene in SW948 ST cells validated in RT-PCR is 
SH3GL2, which is a tumour suppressor frequently deleted or methylated in breast, lung, head and 
neck cancer and glioblastoma (195). FOLR1, folate receptor 1, is reported to be overexpressed in 
breast and ovarian cancer with poor prognosis (196), it is expressed in colorectal cancer tissue as 
well, where it seems to increase the cytotoxicity of 5-fluoro-2'-deoxyuridine (FdUrd) treatment 
(197). We reported also the up-regulation of TGFB2 in SW948 ST cells compared to NC. Its role 
in tumour biology is still controversial but recent studies reported that TGFB2 expression is 
increased in advanced and poorly differentiated CRC and correlates with poor prognosis (198). 
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The last up-regulated gene in SW948 ST is MYEOV, which  has a tumour promoting role in colon 
by increasing cell proliferation and invasion (199). Among the down-regulated genes in SW948 
ST compared to NC we selected for validation FMOD and KLK6. FMOD encodes fibromodulin 
protein, a collagen fibrillogenesis modulator that is highly expressed in cancer stroma increasing 
collagen fibril thickness (200). KLK6 is highly expressed in colorectal cancer cells and promotes 
cell migration and invasion (201). In conclusion, from this analysis we demonstrated the necessity 
to validate with RT-PCR the results obtained with microarray to better understand the biological 
significance underlying our data. In the analysis of the more consistently modulated gene in SW948 
ST cells, we reported the up-regulation of two tumour suppressing genes (OLFM4 and SH3GL2) 
and the downregulation of two tumour promoting transcripts (FMOD and KLK6) which may 
suggest an anti-tumorigenic potential of ST6Gal-I in colorectal cancer. On the other hand, TGFB2, 
MYEOV and FOLR1, with a pro-tumorigenic effect, are up-regulated after ST6Gal-I 
overexpression. Therefore, at present it is not possible to define if the effect of ST6Gal-I 
overexpression results in a tumour promoting or tumour suppressing function in SW948 cell line.   
 
 
Fig. 4.5 mRNA quantification by real time PCR (A) or microarray analysis (B). RNA was extracted from SW948 NC 
and ST cells. The mRNA level determined by RT-PCR was expressed in fold change and normalised on β-Actin 
expression level. The mRNA level evaluated by microarray analysis was expressed in arbitrary units and calculated as 
RNA expression= 2^(log2E-1.3) Where 1.3 is the lowest log2E value of the evaluated genes.  
 
51 
 
In SW48 cells transduced with ST6Gal-I, we found only a few genes reaching a log 2E change 
higher than +/-3; the majority of these were down-regulated. In fact, SW48 ST displayed 18 up-
regulated and 33 down-regulated genes. However, very few of these differentially expressed genes 
are reported to be involved in cancer biology. Among the genes that we validated, only three 
showed a consonant modulation in qPCR; they are MAP1B, MT4 and WNT16 (Fig. 4.6). MAP1B 
is a microtubule associated protein which seems to be important for microtubule stability in 
response to microtubule-targeting anti-cancer drugs (202); moreover, it is involved in cancer cell 
invasion and migration (203). MT4 is a membrane type matrix metalloproteinase and is involved 
in cancer cell invasion and metastasis (204). Eventually, WNT16 is part of WNT family involved 
in cell proliferation. It has been reported that WNT16 is upregulated in gastric adenocarcinoma 
(205) and promotes resistance to chemotherapy in prostate tumour (206). In conclusion, the small 
number of modulated genes suggests a trend towards a tumour suppressive effect of ST6Gal-I 
overexpression in SW48 cell line. These findings show that the effect of ST6Gal-I overexpression 
on the transcriptome of the two colorectal cancer cell lines is very different and strongly cell-type 
specific.  
 
 
Fig. 4.6 mRNA quantification by real time PCR (A) or microarray analysis (B). RNA was extracted from SW48 NC 
and ST cells. The mRNA level determined by RT-PCR was expressed in fold change and normalised on β-Actin 
expression level. The mRNA level evaluated by microarray analysis was expressed in arbitrary units and calculated as 
RNA expression= 2^(log2E-1.3) where 1.3 is the lowest log2E value of the evaluated genes.  
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4.3. PHENOTYPIC CHANGES INDUCED BY ST6Gal-I OVEREXPRESSION 
To assess if the overexpression of ST6Gal-I could alter the phenotype of cancer cells, with special 
focus on the typical hallmarks of cancer, we characterized the ST6Gal-I transduced cells for their 
basic properties. 
 
4.3.1. Anchorage-independent growth  
The ability to grow without adhesion to a solid substrate is a basic hallmark of malignancy. To test 
such ability, we performed soft agar growth assay. In this assay (Fig. 4.7), the cells are plated as a 
single cell within a layer of agar to mimic the growth in absence of adhesion. After two weeks of 
incubation we were able to count the colonies at the microscope. With SW948 ST6Gal-I transduced 
cell line we observed the formation of fewer colonies but of larger dimension compared with their 
negative control (NC). On the other hand, SW48 ST cell line could form a higher number of 
colonies compared with SW48 NC, with no significant difference in colonies dimension.  
 
Fig. 4.7 Reduced adhesion-independent growth of SW948 ST in absence of adhesion compared to NC cells, increased 
colony formation in SW48 ST compared with NC cells. On the left-hand side an example of soft agar growth assay. 
The histogram represents the colonies counted in three biological replicates.   
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4.3.2. Wound healing assay 
To evaluate if ST6Gal-I transduction could alter the ability of the cells to proliferate and migrate, 
we performed wound healing assay using Ibidi culture insert (Fig. 4.8). We observed that ST6Gal-
I overexpression conferred on SW948 ST the ability to heal the wound more rapidly than SW948 
NC, as it is shown in the graph representing the area of the wound. However, a close look to the 
pictures revealed that SW948 ST cells close the wound more rapidly because they tend to 
proliferate first in monolayer and only in a second time as a multilayer. On the contrary, NC cells 
showed a stronger tendency to multi-layer growth. The expression of ST6Gal-I produced an 
opposite effect in SW48. In fact, SW48 NC cells closed faster the wound than SW48 ST6Gal-I 
transduced cells. 
 
 
Fig. 4.8 SW948 ST close more rapidly the wound compared with NC cells, while SW48 ST are less effective in closing 
the wound compared to NC cells. The upper part shows representative pictures of wound healing assay taken at day 0 
and day 7 from the creation of the wound. The histograms show the percentage area of the wound in three biological 
replicates and it is expressed in percentage of the day 0 NC sample. 
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4.3.3. Invasion assay 
With invasion assay we studied the capacity of the two cell lines used as models to invade the 
extracellular matrix. After 24 hours of serum starvation, SW948 and SW48 cells were plated in the 
upper chamber of the transwells. As chemoattractant in the lower chamber we used either complete 
medium supplemented with FBS or serum-free medium with HGF. In both cell types the 
chemiotactic activity of HGF was lower than that of complete medium. However, while in the 
SW948 cell type the expression of ST6Gal-I did not affect the ability of complete medium to drive 
the invasion of the extracellular matrix, the ST6Gal-I expressing SW48 cells displayed reduced 
extracellular matrix invasion (Fig. 4.9). 
 
 
Fig. 4.9 SW948 NC and ST present the same capacity to invade Matrigel, while SW48 ST display a reduced capacity 
to invade Matrigel compared to NC cells. The upper part shows representative pictures of cells that passed through the 
porous membrane of the transwell and invaded Matrigel. The histograms represent the number of invading cells in 
three biological replicates.  
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In conclusion, the experiments reported in this section showed a different response of the two cell 
lines SW948 and SW48, supporting the hypothesis that the effects of ST6Gal-I overexpression can 
be evaluated only in a cell line specific context. 
 
4.3.4. Propensity to apoptosis 
Propensity to apoptosis is a crucial aspect of cancer cell biology. To understand if ST6Gal-I 
expression could modify the response to apoptotic stimuli, we used TPEN, a zinc chelator, to 
activate the intrinsic pathway of apoptosis. To monitor the response, we detected cleaved-PARP at 
0, 4, 8, 16, 24 and 48 hours. Cleaved-PARP is one of the most known markers of apoptosis (207). 
In Western Blot (Fig. 4.10 A), we observed the presence of cleaved-PARP in SW948 ST shortly 
after treatment (4 hours), while it appeared only at 8 hours in SW948 NC. This suggests that the 
transduction with ST6Gal-I in SW948 accelerates the apoptotic response.   
To further investigate how ST6Gal-I overexpression could impact on the apoptotic pathway, we 
used an antibody array kit able to detect 19 proteins involved in the regulation of the stress response 
and apoptosis. We treated again the cells with TPEN, but we considered only short time points: 0, 
4, 8 and 16 hours. After the incubation of the protein extract and the antibody mix on the array 
(refer to methods) we analysed the intensity of the spots resulted by chemiluminescence. Of the 19 
proteins detected by the protein array, we reported only those significantly modulated. In the 
SW948 cell type (Fig. 4.10 B), ST6Gal-I expression results generally in an upregulation of several 
apoptotic stress markers which include p53 (a tumour-suppressor that regulates the cell cycle and 
activates apoptosis in presence of stress) and IκBα phosphorylated on Ser 32/36 (which controls 
NFκB activation in response to different stimuli (208)). The executioner caspases -3 and -7 
displayed similar low level of expression in early time points, reaching a significant higher 
expression in ST6Gal-I expressing SW948 cells only 16 hours after the administration of the 
apoptotic stimulus. The anti-apoptotic P44/42 MAPK (209), appeared to be poorly responsive to 
the apoptotic stimulus. However, its slightly higher constitutive expression in SW948 ST is 
probably due to a subtle stimulation of this pathway. It appears that in the SW948 cell type, the 
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overexpression of ST6Gal-I caused an up-regulation of some apoptotic markers even in absence of 
apoptotic stimulus and an acceleration of the apoptotic response to the stimuli.  
 
 
Fig. 4.10 SW948 cells show an accelerated response to the apoptotic stimulus and increased expression of apoptosis 
and stress markers. SW948 NC and ST were treated with TPEN and collected at different time points. A Western blot 
showing a more rapid increase of cleaved-PARP in ST compared to NC cells. The histogram represents the band 
intensity of cleaved-PARP normalized on β-Actin of three replicates. B Incubation of protein extracts of SW948 NC 
and ST cells after treatment with TPEN resulted in up-regulation of stress and apoptosis markers. The graphs report 
the band intensity normalized on β-Tubulin of three biological replicates.    
 
In the SW48 cell type, ST6Gal-I failed to induce acceleration of PARP cleavage, as detected by 
Western blot analysis (Fig. 4.11 A). Analysis with the antibody array kit (Fig. 4.11 B) revealed a 
similar basic level of expression in ST6Gal-I-transduced and control cells of most apoptotic 
markers, with the exception of IκBα phosphorylated on Ser 32/36. It was found only an increased 
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expression of the antiapoptotic P44/42 MAPK at the 4 h time point, of p53 at 8h and 16h time 
points and of Chk1 (which plays an important role in DNA damage checkpoint control (210)) at 
8h time point. Overall these data indicate that the effect of ST6Gal-I expression on the propensity 
to undergo apoptosis along the intrinsic pathway is nearly undetectable in SW48 cells. These 
findings suggest that the protein array is a more sensitive technique, compared with Western Blot, 
in fact is able to detect even slight differences in the level of activation of proteins involved in the 
apoptosis pathway. Furthermore, with these results we proved that the effect of ST6Gal-I 
overexpression on the propensity to apoptosis is specific for the cell line analysed. 
 
 
Fig. 4.11 In SW48 the expression of ST6Gal-I does not alter the apoptotic response compared to NC cells. Similar 
modulation of stress and apoptosis markers in SW48 NC and ST. SW48 NC and ST were treated with TPEN and 
collected at different time points. A Western blot showing a similar kinetics of cleaved-PARP in ST and NC cells. The 
histogram represents the band intensity of cleaved-PARP normalized on β-Actin of three replicates. B Incubation of 
protein extracts of SW48 NC and ST cells after treatment with TPEN resulted in an unaltered expression of stress and 
apoptosis markers. The graphs report the band intensity normalized on β-Tubulin of three biological replicates.     
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4.3.5. HGF-induced substrate phosphorylation 
To investigate if the overexpression of ST6Gal-I could affect the intracellular signalling in response 
to growth factors, we treated SW948 and SW48 cells with HGF that stimulates cell proliferation 
and migration. Cells were serum starved for 24 hours to minimize the effects of growth factors 
contained in serum and treated with HGF for short times. We analysed the intracellular signalling 
using anti-pFAK (Tyr397) and anti-phosphotyrosine antibodies (Fig. 4.12) by Western blotting. 
We noticed that pFAK (Tyr397) levels were significantly higher in untreated SW948 ST than in 
untreated SW948 NC.  In SW948 NC, cells pFAK decreased progressively during HGF treatment, 
reaching the lowest value at 120 minutes, while in SW948 NC it rose gradually during treatment 
time. We evaluated also the changes in the tyrosine phosphorylation induced by HGF, choosing 
phosphoproteins of 125, 60 and 25 kDa as they were the most abundant in our extracts. Although 
the differences did not reach statistical significance, the trend was similar to that observed for 
pFAK (Tyr397): an increased level in ST without HGF treatment, an increase of the 
phosphorylation levels in SW948 NC and a decrease in SW948 ST from 0 to 120 minutes. 
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Fig. 4.12 FAK phosphorylation at Tyr397 is higher in SW948 ST compared with NC in the untreated samples. Then, 
during treatment with HGF it increases in SW948 NC cells and decrease in ST cells. SW948 NC and ST were treated 
with 25 ng/ml HGF for 0, 15, 30 and 120 minutes. The histograms represent pFAK (Tyr397) and phosphoproteins at 
125, 60 and 25 kDa band intensity normalized on β-Actin of three independent experiments.    
 
On the other hand, treatment of SW48 NC and ST with HGF failed to induce significant changes 
of the levels of pFAK (Tyr397), and of the 125 and 60 kDa phosphoproteins which were similar in 
the two cell lines (Fig. 4.13). We observed only a modulation in the phosphorylation levels of the 
25 kDa phosphoproteins which increased gradually during time in SW48 NC, but not in SW48 ST, 
without reaching statistical significance.  
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Fig. 4.13 FAK phosphorylation at Tyr397 is similar in SW48 ST compared with NC cells with and without HGF 
treatment. SW48 NC and ST were treated with 25 ng/ml HGF for 0, 15, 30 and 120 minutes. The histograms represent 
pFAK (Tyr397) and phosphoproteins at 125, 60 and 25 kDa band intensity normalized on β-Actin of three independent 
experiments.    
 
Treatment with EGF according to the same protocol did not induce significant changes.  
 
4.3.6. ST6Gal-I overexpression and stemness 
Recent studies reported that ST6Gal-I could be involved in the regulation of pluripotency (186) 
and that it correlated with stem cell markers in colon cancer cell lines (187). Therefore, we 
investigated if in our models the overexpression of ST6Gal-I could induce the expression of stem 
cell markers. We used ALDEFLUOR to detect the activity of aldehyde dehydrogenase (ALDH) 
which is reported to be a stem cell and a cancer-initiating cell marker in many tissues, including 
colon (211). We performed two experiments for each cell line, that are reported in Fig. 4.14 and 
4.15, incubating SW948 and SW48 NC and ST with ALDEFLUOR reagent or DEAB (a specific 
ALDH inhibitor) for negative control.  We observed that the majority of SW948 cells were positive 
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to ALDH compared to the control sample (with DEAB) (Fig. 4.14), but without relevant 
differences due to ST6Gal-I overexpression.  
 
 
Fig. 4.14 The majority of SW948 cells resulted positive for ALDH compared to the control with DEAB. SW948 NC 
and ST cells did not present any significant difference. SW948 NC and ST were incubated with ALDH with and 
without DEAB (inhibitor of ALDH) for 30 minutes at 37°C. A gate to identify ALDH positive cells was drown 
according to the cell population in the control sample in a dot plot SSC/FL1. The table reports the percentage of ALDH 
positive cells in two independent experiments.      
 
Nevertheless, when we performed the experiment with SW48, we saw that the percentage of ALDH 
positive cells was much lower compared to SW948, indicating that only a limited portion of cells 
presented high ALDH activity and thus cancer stem cells characteristics. Moreover, we observed 
that the SW48 ST cells presented a lower number of ALDH positive cells compared to NC, even 
though the difference was not statistically significant (Fig. 4.15). These results suggest the presence 
of potential cancer stem cells in SW948 and SW48 cell lines, although ALDH staining failed to 
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reveal differences due to ST6Gal-I overexpression. Therefore, the presence of cancer stem cells in 
relation with ST6Gal-I overexpression must be further investigated. 
 
  
Fig. 4.15 Only a portion of SW48 cells resulted positive for ALDH compared to the control with DEAB. SW48 ST 
presented a lower percentage of ALDH positive cells compared to NC, but the difference did not reach statistical 
significance. SW48 NC and ST were incubated with ALDH with and without DEAB (inhibitor of ALDH) for 30 
minutes at 37°C. A gate to identify ALDH positive cells was drown according to the cell population in the control 
sample in a dot plot SSC/FL1. The table reports the percentage of ALDH positive cells in two independent experiments.      
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5. DISCUSSION 
 
In this study, we aimed to elucidate the role of ST6Gal-I in colorectal cancer and better characterise 
its pro- or anti-tumour potential. In fact, many in vivo and in vitro experiments highlight the 
importance of ST6Gal-I in tumour development and progression (97, 99, 104-106), while other 
studies report a more pronounced malignancy in its absence (109, 113-116, 121). To clarify the 
role of ST6Gal-I in clinic we performed an evaluation of ST6Gal-I mRNA expression in correlation 
with clinical data using the TCGA public database that includes a high number of cancer patients. 
We observed that the median value of ST6Gal-I expression was similar between normal and cancer 
tissue in contrast to what observed previously by many studies at the protein level (33, 93-97) 
although in a limited number of patients. However, the level of ST6Gal-I mRNA expression was 
extremely variable among patients, allowing to investigate correlations between ST6Gal-I mRNA 
level and clinical parameters. We observed that low levels of ST6Gal-I mRNA expression 
correlated with high MSI, supporting data showing that high SNA reactivity was correlated with a 
microsatellite-stable phenotype (98). In the same direction goes the observation that low ST6Gal-
I expression is correlated with BRAF mutation, in fact it has been reported that BRAF is commonly 
mutated in MSI colon cancer (212). On the other hand, ST6Gal-I mRNA expression did not 
correlate with clinical stage, mutation in KRAS, APC and TP53, response to therapy and overall 
survival. These findings are in contrast with previous data reporting a worse prognosis for CRC 
patients presenting high ST6Gal-I and or SNA reactivity (96, 97). However, data in TCGA 
database are based only on mRNA expression and not on enzyme activity that has been reported 
to increase in CRC tissue compared with normal mucosa (189).   
From previous experiments performed by our group and from literature data, we hypothesised that 
the role of each glycosyltransferase in cancer progression can be cell-type specific, depending on 
the genetic and transcriptional background of the specific cancer specimen and to many factors that 
can regulate glycosyltransferase activity, including the presence of the donor and acceptor 
substrates. Therefore, we studied two cell models that overexpressed ST6Gal-I from cell lines 
lacking the endogenous form of the enzyme both derived from colon cancers but representing the 
two principal mechanisms for carcinogenesis in colon. In fact, SW948 and SW48 cell lines have 
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been isolated from CRCs originated through chromosomal instability or microsatellite instability, 
respectively. To confirm the overexpression of the enzyme we evaluated the presence of the 
mRNA, the protein itself and the reactivity to the lectin SNA that detects the presence of ST6Gal-
I product. In this regard we noticed a discrepancy between the level of mRNA and protein 
expression in NC cells and the reactivity to SNA. This can be partially explained considering that 
NC cells present a low but detectable level of enzymatic activity and that the higher level of activity 
of SW48 NC, compared with SW948 NC, is consistent with higher reactivity to SNA in 
immunofluorescence and FACS analysis. In addition, we failed to observe a differential SNA 
reactivity between SW948 and SW48 NC and ST in western blot with denaturing and reducing 
conditions, while we obtained a consistent difference between NC and ST in both SW948 and 
SW48 in native conditions with the addition of 1% Triton-X100 in the sample mix. This could 
suggest the requirement of the glycoproteins in their native structure for SNA recognition of the 
ligand. Moreover, it is noteworthy that lectins’ specificity for their ligands is considerably lower 
than that of antibodies In particular, SNA lectin can recognize, together with the sialic acid linked 
via α2,6 linkage to Gal, also that α2,6- linked to GalNAc (sialyl-Tn), whose addition is catalysed 
by ST6GalNAc-I. Thus, a low level of SNA reactivity can be present even in cell lines lacking 
ST6Gal-I.   
From a transcriptomic analysis of our cell models, we noticed that the gene modulation induced by 
ST6Gal-I expression was very different in the two cell lines, with SW948 presenting a higher 
number of altered genes compared to SW48. Moreover, none of the differentially expressed genes 
resulted modulated in both cell lines. These demonstrates that the impact of ST6Gal-I 
overexpression is cell type specific.  
In SW948 and SW48 cells, we reported several genes differently modulated by ST6Gal-I that we 
selected for validation by real time RT-PCR, based on their potential role in cancer. Not all of them 
were confirmed to be modulated using real time PCR. This suggests that even though 
transcriptomic analysis is a very useful and powerful tool to identify modulated genes in a 
particular context, its results always need to be verified. The two techniques provided consistent 
results for the upregulation of OLFM4, SH3GL2, FOLR1, TGFβ2, MYEOV and downregulation 
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of FMOD and KLK6 in SW948, while in SW48 cell we observed only three downregulated genes: 
MAP1B, MT4 and WNT16.  
OLFM4 resulted to be the most up-regulated in SW948 ST cells. OLFM4 is a secreted glycoprotein 
overexpressed in both primary (193, 213), and liver metastasis (214) of colon tumours. OLFM4 is 
also considered a marker of stem cells(215), in fact its expression is localized in colon crypts where 
the stem cell niche is located (214). OLFM4 is regulated by the transcription factor NFκB and it 
seems to play a role in resistance to apoptosis (216). In fact, it binds to GRIM-19 a protein known 
to facilitate apoptosis induced by a combination of interferon β and retinoic acid treatment (217). 
Interestingly, it interacts with cell surface proteins, such as cadherins, therefore suggesting a role 
in cell adhesion. It has been reported that OLFM4 deletion in a pancreatic cancer model reduced 
cell proliferation, in contrast to previous data showing that overexpression of OLFM4 reduced cell 
proliferation in prostate cancer (218) or did not affect proliferation in a colon cancer cell line (219). 
On the other hand, OLFM4 deletion induced colon adenocarcinoma formation in mice 
heterozygous for Apc inactivation (a model for intestinal tumorigenesis) because of its negative 
regulation of the Wnt/β-catenin pathway (194). Altogether, these studies indicate that OLFM has 
a double-edge role, probably dependent on the cell context.    
A second gene up-regulated in SW948 ST cell is SH3GL2 (or endophilin I), which is involved in 
clathrin-mediated endocytosis (220). It has been reported that this protein regulates EGFR 
endocytosis and degradation in laryngeal carcinoma (221), non-small cell lung cancer (222), head 
and neck squamous cell carcinoma (223) and urothelial carcinoma (224), therefore this gene is 
considered a tumour-suppressor and is frequently down-regulated in these and other malignancies. 
In glioblastoma cells, SH3GL2 is down-regulated through the action of mir-330 with a consequent 
activation of the ERK and PI3K/AKT signalling pathway (195). Moreover, loss of SH3GL2 
promotes the migration and invasion of glioblastoma cells through activation of  the STAT3/MMP2 
signalling pathway (225). In addition, in breast cancer cells the overexpression of SH3GL2 reduced 
tumour growth promoting the release of cytochrome C from mitochondria and, thus, promoting 
apoptosis (226). However, its role in colorectal cancer has not been investigated yet. 
FOLR1 is overexpressed in tumours, mainly from epithelial origin. It has been reported that it 
increases cell proliferation by activating Erk 1/2, c-Jun and c-Fos pathway (196). It is 
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overexpressed in lung adenocarcinoma, in non-small cell lung cancer and in metastatic lymph 
nodes from lung primary tumours (227-229). In breast cancer, the overexpression of FOLR1 is 
associated with increased risk of recurrence in triple-negative cancer, therefore it could be useful 
as a marker for this type of malignancy (196, 230). Moreover, FOLR1 is overexpressed in tumours 
from female genital tract such as cervical cancer (196), endometrium carcinoma and uterine 
adenocarcinoma (231) and ovarian cancer with aggressive phenotype (232). The presence of 
FOLR1 in sera from patients with ovarian cancer has been proposed as an early diagnosis 
marker(233). There are no published evidences of FOLR1 overexpression in colorectal cancer 
compared to normal mucosa (234), although TCGA data report an average values of 5 and 157 in 
normal and cancer tissue, respectively. It has been reported that its expression increases the efficacy 
of 5-fluoro-2'-deoxyuridine (FdUrd) treatment (197). 
TGFβ2 is a secreted cytokine part of the TGFβ superfamily. They bind various TGF-beta receptors 
leading to recruitment and activation of SMAD family transcription factors regulating gene 
expression. One of the gene transcribed after TGFβ signalling is p21 which halts the cell cycle 
inhibiting CDK2 activity (235). In fact, one of the most known function of TGFβ family is to inhibit 
epithelial cells proliferation (236). However, more recently TGFβ signalling pathway has been 
considered as both a tumour suppressor and a cancer promoter (237), in fact it seems to inhibit the 
proliferation of normal epithelial and tumour cells at early stages of the disease and to cause the 
opposite effect on malignant and stroma cells in more advanced tumours (238). This switch is 
operated by a mechanism still not elucidated, probably concerning mutation in mediators of the 
tumour-suppressive pathway enhancing the tumour-promoting one (i.e. mutations on SMAD 
proteins occurs in 10% of CRC) (239). Increased secretion of TGFβ by the tumours exerts an effect 
on both the microenvironment and the tumour itself. In fact, it creates the permissive stroma that 
support tumour growth and spread, but also induces on cancer cell epithelial to mesenchymal 
transition (EMT) and appearance of stem cell–like traits (240). In particular, in colorectal cancer, 
TGFβ2 is overexpressed in advanced tumours and correlates with poor prognosis (198).  
MYEOV (myeloma overexpressed) is localized at chromosome 11q13, a frequent site for 
chromosomal rearrangements in various carcinomas, moreover it is co-expressed with Cyclin1 and 
overexpressed in many malignancies (241), including neuroblastoma cell lines (242), cervical 
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lymph node metastasis of oral squamous cell carcinoma (243), oesophageal carcinoma cell 
lines(244) and in primary plasma cell leukaemia (245). Moreover, in colorectal cancer cells it 
induces migration and invasion (199, 246).  
FMOD and KLK6 resulted downregulated in our analysis. FMOD, fibromodulin protein, is a 
collagen fibrillogenesis modulator. It is highly expressed in cancer stroma resulting in a dense 
extracellular matrix that functions as a tumour barrier (200). Moreover, it has been reported that 
FMOD is involved in angiogenesis in small cell lung cancer as a result of increased expression of 
angiogenic factors (247), is essential for glioma cells migration through its ability to induce 
filamentous actin stress fibre formation (248) and is overexpressed in prostate cancer (249).      
KLK6, or kallikrein 6, is a serine protease member of the S1 family of protein peptidase. It is 
overexpressed in many malignancies, including breast (250), ovarian (251) and prostate cancer 
(252), and in melanoma and head and neck cancer (253). It has been reported to be upregulated 
also in colorectal cancer and in metastatic lymph nodes in association with poor prognosis (254, 
255). In fact, several studies report that it is regulated by oncogenic Ras and that it can enhance 
colon cancer cells migration (201) and metastasis formation (254). On the basis of these studies it 
is not possible to predict a clear oncogenic or tumour-suppressor role of ST6Gal-I in SW948 cells. 
In fact, ST6Gal-I overexpression resulted in four up-regulated tumour-promoting genes (OLFM4, 
TGFβ2, MYEOV and FOLR1), but on the other hand two tumour-promoting genes were 
downregulated (FMOD and KLK6) while one tumour-suppressor gene (SH3GL2) was up-
regulated.  
In SW48 cells, results from microarray analysis and real time-PCR were consistent only for three 
downregulated genes: MAP1B, MT4 and WNT16. MAP1B is a microtubule-associated protein 
that contributes to migration and invasion in gastric cancer cells (203). Moreover, it is involved in 
resistance to mTOR inhibitors in glioblastoma cells (256) and is considered a novel paraneoplastic 
marker for neurological diseases with a predictive value for small cell lung carcinoma (257). 
However, it has been reported that MAP1B is part of a signature of methylated genes that define 
the small portion of CpG islands methylated phenotype (CIMP) in microsatellite stable (MSS) 
colon cancer (258). MT4 is a membrane type matrix metalloproteinase and plays an important role 
in cancer cell invasion and metastasis. In fact, it is highly expressed in lipid rafts of a metastatic 
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colon cancer cell line (204), in melanoma cell lines and tissue samples (259), in breast, oral and 
gastric cancer (260-262). WNT16 is part of the Wnt signalling pathway and is involved in cell 
proliferation. WNT16 is overexpressed in many tumours, including gastric and cervical cancer 
(205, 263) and promotes resistance to chemotherapy in prostate tumour (206). Moreover, it is 
produced from the tumour microenvironment and promotes the advancing of malignancies (264). 
All together, these data suggest that in SW48 the overexpression of ST6Gal-I promotes the down-
regulation of tumour-promoting genes. However, the extent of its tumour suppressive potential 
results limited considering the small number of genes modulated by its overexpression.  
The phenotypic changes induced by the overexpression of ST6Gal-I in SW948 and SW48 cells 
were not overlapping and sometimes they were divergent. We found that SW948 ST cells formed 
less colonies but of larger size when grown in adhesion-independent conditions. This means that 
only a minority of the population had the potential to grow in these conditions, but these cells were 
provided with accelerated proliferation. This could suggest the presence of a limited portion of 
cancer stem cells in SW948 ST compared to NC, but our data obtained with ALDH staining do not 
confirm this hypothesis. In the scratch wound test, we observed an accelerated closure of the wound 
by SW948 ST, due to their higher propensity to grow in monolayer compared to NC cells. This 
finding is consistent with what previously observed by our group in clones of SW948 cells 
transfected with rat ST6Gal-I (109). Two genes putatively involved in adhesion and motility: 
CNTN5 (265) and PHACTR3 (266) which displayed up-regulation in SW948 ST could be 
responsible for this phenotype, although we did not find differences in the capacity to invade 
Matrigel. In the cell type SW48, ST6Gal-I expression results in very different phenotypic effects. 
In fact, SW48 ST cells displayed reduced ability to close the scratch wound and poorer capacity to 
invade Matrigel compared to their negative control and no difference was observed in adherence-
independent growth. Among the transcriptomic data which could explain this phenotype is the 
down-regulation in ST cells of two genes involved in cell motility and invasion: MAP1B and MT4.  
Resistance to apoptosis is one of the hallmarks of cancer. We evaluated the propensity of SW948 
and SW48 transduced cells to undergo apoptosis after treatment with TPEN, which induces the 
activation of the intrinsic pathway. We obtained different results in the two cell lines. In SW948 
cells, the overexpression of ST6Gal-I caused an acceleration of apoptotic response induced by 
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TPEN. Moreover, data from the protein array indicated that in SW948 ST the markers associated 
with apoptosis and stress pathways were detectable also in absence of the apoptotic stimulus, thus 
suggesting a cellular environment more prone to undergo apoptosis. By contrast, in SW48 cells we 
did not observe any difference in the apoptotic kinetics between NC and ST and only marginal 
differences with the antibody protein array. These results support the idea of a cell-type specific 
effect of ST6Gal-I and point towards an acceleration of the apoptotic process in the SW948 cell 
line, in apparent conflict with studies reporting that ST6Gal-I has an important role in protection 
from apoptosis. In fact, the sialylation of β1-integrin, that binds galectin 3 which sometimes 
induces apoptosis (133), of the TNFR1, the receptor of  TNF-α (134), and of the Fas-death receptor 
(135) prevents the binding with their ligands and the induction of apoptosis. However, these 
receptors only activate the apoptosis via the extrinsic pathway. Consequently, their impairment is 
due to their inability to bind the ligand, not to a modification of the apoptosis machinery. In a very 
recent study, it has been reported that ST6Gal-I protects cancer cells of pancreatic or ovarian origin 
from the apoptotic effects of serum growth factors withdrawal (136). The most likely interpretation 
for this discrepancy with our data is the strong cell type specificity of these phenotypic traits. 
A differential ST6Gal-I expression apparently results in a slightly higher constitutive FAK 
phosphorylation, even in the absence of EGF or HGF treatment, but only in SW948 cells. Other 
tyrosine residues do not appear to be differentially phosphorylated. Overall, these results are 
consistent with the observed properties of SW948 ST cells in the scratch wound test.   
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6. CONCLUDING REMARKS 
 
The data obtained in this work comprehensively suggest that the overexpression of ST6Gal-I can 
impact on the gene expression of the cell. This is not obvious if one considers that glycosylation is 
a secondary gene product, which modifies mainly glycoproteins located on the cell surface. It is 
reasonable to hypothesize that differentially 2,6-sialylated cell surface molecules, including 
growth factor receptors, display differential ability to trigger a signal transduction cascade towards 
the nucleus, resulting in modulation of cell transcription. This effect on gene transcription, though, 
is strictly cell-type specific due to the differences in the number and type of modulated genes that 
we observed by transcriptomic analysis in the two cell lines examined. The subtle but evident 
phenotypic changes in ST6Gal-I expressing cells can consequently be explained by two partially 
overlapping mechanisms: a direct modulation of cell membrane receptors (for example the strength 
of the binding of integrins to their substrates) and the modulation of gene expression. Although 
transcriptomic and phenotypic analysis of ST6Gal-I expressing cells does not allow to clearly 
establish whether this modification has a general effect of promoting or inhibiting malignancy, 
there is no doubt that the effect is strongly cell-type specific. According to this view, it is not 
surprising that literature data report sometimes conflicting observations. Current results showing 
phenotypic changes of moderate entity, are consistent with what we deduced from TCGA database. 
In fact, ST6Gal-I expression in colorectal cancer has no impact on survival, response to therapy or 
tumour stage, indicating the lack of a close association between ST6Gal-I expression level and 
malignancy. Furthermore, mice knockout for ST6Gal-I present normal development and a grossly 
normal phenotype with only defects in  IgM production (118) and granulopoiesis (119). In addition, 
in a mouse model of breast cancer, ST6Gal-I KO leads to the development of more differentiated 
tumours with lower FAK signalling without effects on tumour growth (120). 
However, in cancer biology even subtle differences can be important in regulating cell behaviour 
and consequently the clinical course of the disease. For this reason, the role of ST6Gal-I in 
malignancy deserves further investigations.     
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